



**DOMINION  
MINERALS**

**Dominion Minerals Limited (Formerly Factor  
Therapeutics Limited)**

**Annual Report**

For the year-ended 31 December 2021

ABN: 45 101 955 088

For personal use only

CONTENTS

Directors' report	3
Auditor's independence declaration	14
Consolidated statement of profit or loss and other comprehensive income	15
Consolidated statement of financial position	17
Consolidated statement of changes in equity	18
Consolidated statement of cash flows	19
Notes to the financial statements	20
Directors' declaration	42
Independent auditor's report	43
Shareholder Information	48
Corporate directory	51

## DIRECTORS' REPORT

Your Directors present their report on Dominion Minerals Limited (formerly Factor Therapeutics Limited) ("Company" or "Dominion") for the financial year ended 31 December 2021. Dominion is an entity incorporated and domiciled in Australia and is listed on the Australian Securities Exchange with the code DLM (ASX:DLM). The financial statements to which this report relate represent the financial statements of Dominion and the entities it controlled for the year ended 31 December 2021 (collectively "Group").

The names and qualifications of Directors in office during the financial year and up to the date of this report are detailed below. Directors were in office for the entire period unless noted otherwise.

- Dr David Brookes Chairman
- Mr Anastasios Arima Non-Executive Director (appointed 1 November 2021)
- Mr Dominic Allen Executive Director and CEO (appointed 1 November 2021)
- Mr John Michailidis Non-Executive Director (resigned 1 November 2021)
- Ms Melanie Farris Non-Executive Director (appointed 20 April 2021, resigned 1 November 2021)
- Dr Christian Behrenbruch Non-Executive Director (resigned 28 May 2021)

### **Dr David Brookes, MBBS FACRRM FAICD**

#### **Non-Executive Director and Chairman**

*Appointed Non-Executive Director 10 April 2019. Appointed Chairman 30 July 2020*

Dr Brookes has extensive experience in the health and biotechnology industries and is currently a Non-Executive director of Anatar Ltd (ASX:ANR) and TALi Digital Limited (ASX:TD1). He has previously been a director of several other ASX listed biotechnology companies, most recently as the Chairman of genomics solutions company, RHS Ltd, which was acquired by PerkinElmer Inc (NYSE:PKI \$9B biotech company) in June 2018. Until its acquisition in January 2021, Dr Brookes was Non-Executive Chairman of a private health services company, the Better Medical Group, and maintains roles as a clinician and a biotechnology industry consultant. Dr Brookes is a Fellow of the Australian College of Rural and Remote Medicine and a Fellow of the Australian Institute of Company Directors.

### **Anastasios Arima**

#### **Non-Executive Director**

*Appointed 1 November 2021*

Mr Arima is a resource company executive with a strong history of identifying company-making resource projects. He was the founder of Piedmont Lithium (Nasdaq:PLL) and was instrumental in identifying and securing the Piedmont Lithium Project in North Carolina, USA. Mr. Arima is the founder and managing director of Hyperion Metals (ASX:HYM), focused on the development of the titan heavy mineral sand project and associated titanium metal technologies in Tennessee, USA. He has extensive experience in the formation and development of energy and resource projects in North America and Europe. He attended the University of Western Australia where he earned a Bachelor of Commerce whilst studying for a Bachelor of Engineering.

### **Dominic Allen**

#### **Executive Director and Chief Executive Officer**

*Appointed 1 November 2021*

Mr Allen is a finance professional with over 15 years' experience in the management and operations of natural resources organisations. Mr Allen is currently head of corporate development for Hyperion Metals (ASX:HYM), focused on the development of the titan heavy mineral sand project and associated titanium metal technologies in Tennessee, USA, having previously held senior roles with major resource organisations Rio Tinto Limited and Oyu Tolgoi LLC. Mr Allen commenced his career in the corporate finance team of international accounting firm Ernst & Young, holds a Bachelor of Commerce and a Bachelor of Science (Hons) from the University of Western Australia and is a qualified Chartered Accountant (CA ANZ).

**Mr John Michailidis, BSc (Hons) EMBA (HARV) MAICD**

**Non-Executive Director**

*Appointed Non-Executive Director 14 February 2017. Resigned 1 November 2021.*

Mr. Michailidis is currently the Managing Director for TEVA Australia/NZ and brings over 30 years of commercial pharmaceutical experience to Factor, most recently as Managing Director for TEVA, Australia and New Zealand. His career has ranged from global franchise and regional executive leadership roles with F. Hoffman – La Roche (Roche) to CEO experience with growth-stage biopharmaceutical companies, such as AviPep and Orphan Australia (acquired by Sigma). Mr. Michailidis holds a BSc in Genetics from LaTrobe University, and executive business qualifications from Harvard Business School and INSEAD.

**Ms Melanie Farris (FGIA, FCG, GAICD) BComn Grad Dip ACG**

*Appointed Non-Executive Director 20 April 2021. Resigned 1 November 2021*

Ms Farris is an experienced governance and corporate operations professional and non-executive director with over 13 years' experience in listed life sciences companies, as well as extensive experience in the planning, management and delivery of strategic corporate activities including IPO and M&A due diligence and integration. Ms Farris previously served as Non-Executive Director and Company Secretary for Invion Limited (ASX:IVX); and Chairperson of Synapse Australia Limited. She is currently Chief Governance and Risk Officer and Group Company Secretary for Telix Pharmaceuticals Limited (ASX:TLX). Melanie holds a Bachelor of Communication (Public Relations), and a Graduate Diploma in Applied Corporate Governance. She is a Fellow of the Governance Institute of Australia, a Fellow of the Chartered Governance Institute (UK) and a Graduate of the Australian Institute of Company Directors.

**Dr Christian Behrenbruch, BEng(Hons) DPhil(Oxon) MBA JD GAICD**

**Non-Executive Director**

*Appointed Executive Director 12 October 2015; Non-Executive Director effective 1 June 2017. Resigned 28 May 2021*

Christian Behrenbruch has over 15 years of C-level leadership experience in the medtech, biotechnology and healthcare IT space, and has significant experience as a director of commercial and non-profit organisations. His former CEO/Director-level appointments include Mirada Solutions (now Siemens Plc), Fibron Technologies and ImaginAb, Inc. He is a former director of Momentum Biosciences LLC, Siemens Molecular Imaging Ltd, Radius Health Ltd (now Adaptix), Cell Therapies P/L (Peter MacCallum Cancer Centre) and the Oncidium Foundation. He is currently the Managing Director and CEO of Telix Pharmaceuticals Limited (ASX:TLX), Chairman of Monash Engineering and IT Foundation Board and is a Professorial Fellow at Monash University.

**DIRECTORS' INTERESTS IN COMPANY SECURITIES**

	Number of Ordinary Shares <sup>#</sup>	Number of Options over Ordinary Shares <sup>#</sup>
D Brookes	4,901,250	500,000
D Allen	2,410,624	1,303,541
A Arima	910,624	1,303,541

## DIRECTORS' MEETINGS

The number of meetings of Directors and committees of Directors held in the financial year ended 31 December 2021, and the number of meetings attended by each Director, is listed below.

	Directors' Meetings		Audit and Risk Management Committee		Nomination Committee		Remuneration Committee	
	Eligible to Attend	Attended	Eligible to Attend	Attended	Eligible to Attend	Attended	Eligible to Attend	Attended
D Brookes	14	14	1	1	-	-	-	-
D Allen <sup>(i)</sup>	1	1	-	-	-	-	-	-
A Arima <sup>(i)</sup>	1	1	-	-	-	-	-	-
J Michailidis <sup>(ii)</sup>	13	13	1	1	-	-	-	-
M Farris <sup>(iii)</sup>	7	7	-	-	-	-	-	-
C Behrenbruch <sup>(iv)</sup>	8	6	-	-	-	-	-	-

(i) Appointed 1 November 2021.

(ii) Resigned 1 November 2021.

(iii) Appointed 20 April 2021, resigned 1 November 2021.

(iv) Resigned 28 May 2021.

The full Board fulfilled the roles of the Audit and Risk Management Committee, the Remuneration Committee and the Nominations Committee during the financial year.

## COMPANY SECRETARY

### **Stephen Kelly (Chief Financial Officer and Company Secretary)**

*Appointed 8 October 2021*

Mr Kelly is a highly experienced Director, Chief Financial Officer and Company Secretary. A qualified Australian Chartered Accountant, Mr Kelly has more than 30 years international experience in the areas of external and internal audit, risk management and compliance, treasury and corporate finance across a range of industry sectors including agribusiness, mining, infrastructure, property development and banking and finance. Mr Kelly is a member of the Institute of Chartered Accountants in Australia.

Melanie Farris served as Company Secretary from 1 January 2021 to 1 November 2021.

## PRINCIPAL ACTIVITIES – REVIEW OF OPERATIONS

### **Acquisition of PowerLime Inc, capital raising and re-listing of the Company's shares on the ASX**

Following the receipt (in November 2018) of negative clinical trial results for the Company's previous lead asset (VF001), the activities of the Company were directed to the identification and diligence of potential new business opportunities.

On 24 July 2020, ASX determined that the securities of the Company would be suspended from quotation and that, following any approval by Shareholders of a commercial transaction, ASX would exercise its discretions under Listing Rule 11.1.3 to require the Company to re-comply with Chapters 1 and 2 of the Listing Rules.

On 25 January 2021, the Company appointed Taylor Collison Limited as a Corporate Advisor to assist in introducing commercial opportunities.

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
DIRECTORS' REPORT  
31 DECEMBER 2021**

In March 2021, the Company commenced negotiations with PowerLime, Inc. (PowerLime), a company associated with the Apollo Group (Apollo). Apollo is an investment and management group with more than 20 years of success in the natural resources sector.

On 20 April 2021, the Company announced it had entered into a non-binding term sheet for the acquisition of PowerLime, Inc. and its assets ("PowerLime"). PowerLime holds an option under an Option Agreement to acquire a land parcel located in Early County, South Georgia, USA to explore and develop an advanced high calcium limestone project.

The proposed transaction would result in a significant change in the nature and scale of the Company's activities away from life sciences and into the resources sector, and in accordance with the ASX Listing Rules was conditional upon (amongst other things) the Company obtaining the approval of Shareholders.

Shareholder approvals were received at the Company's Extraordinary General Meeting ("EGM") held on 9 September 2021 and on the same date the Company issued a replacement prospectus to raise A\$4,000,000 of capital (before costs and expenses) by the issue of 100,000,000 fully paid ordinary shares at an offer price of A\$0.04. At the EGM shareholders also approved a 10:1 consolidation of the Company's equity securities.

On 27 September 2021, the Company completed the acquisition of all the issued capital of PowerLime. As consideration for the acquisition of PowerLime, the Company issued 18,750,000 shares to PowerLime's shareholders at A\$0.04 per share, 6,249,998 options to PowerLime shareholders and 4,437,500 options to the management team of PowerLime<sup>1</sup>. The options are exercisable at \$0.12 per option and expire on 16 September 2025. The Company also paid the second option payment of US\$150,000 payable by PowerLime under the option which grants PowerLime the right to acquire the real property located in Early County, South Georgia on which the Georgia Lime Project is located, and legal costs incurred by PowerLime in relation to the transaction.

On 27 September 2021, the Company changed its name to 'Dominion Minerals Limited' and its ASX code to 'DLM'.

On 8 October 2021 the Company announced the completion of the public offer to raise A\$4,000,000 through the issue of 100,000,000 fully paid ordinary shares at an offer price of A\$0.04.

On 1 November 2021 the Company's securities were reinstated to official quotation on the ASX and the Company's Board of Directors was restructured with the appointment of Anastasios Arima and Dominic Allen and the resignation of John Michailidis and Melanie Farris as Directors.

#### **Georgia Lime Project, Georgia, USA**

PowerLime holds a 100% interest over the Georgia Lime Project, comprised of an option to purchase ~360 acres of private surface and mineral rights in Early County, Georgia. The Georgia Lime Project has been shown as prospective for high calcium lime through significant exploration work previously undertaken by PowerLime, including the drilling of 8 sonic holes and 8 test pits, which identified intersections of up to 10 metres of high calcium limestone generally grading 96% to 97% CaCO<sub>3</sub> from near surface. The project presents the potential to rapidly define a mineral resource of high calcium limestone in a region where significant baseload demand exists in the form of agricultural lime, which is currently predominately supplied by Florida based limestone and dolomite operations.

Following the acquisition of PowerLime and the completion of the capital raising, Dominion completed a 13-hole diamond drill program. The results from the program confirmed a property wide deposit of high calcium limestone occurring beneath a thin veneer of unconsolidated overburden. All 13 holes intersected thick intervals of high calcium limestone. Assays included<sup>2</sup>:

- Starting at 5.9m: **8.6m @ 97.0% CaCO<sub>3</sub>**
- Starting at 4.3m: **9.7m @ 96.1% CaCO<sub>3</sub>**
- Starting at 3.2 m: **9.6m @ 96.1% CaCO<sub>3</sub>**
- Starting at 6.1m: **8.9m @ 96.1% CaCO<sub>3</sub>**
- Starting at 1.5m: **8.1m @ 96.0% CaCO<sub>3</sub>**
- Starting at 5.2m: **8.9m @ 95.9% CaCO<sub>3</sub>**

Following the success of the drill program, Dominion commenced work on the preparation of a maiden mineral resource estimate for the Georgia Lime Project and appointed respected North American engineering firm Marshall Miller & Associates to commence initial technical studies.

<sup>1</sup> The number of securities and issue price / exercise price per security issued as consideration for the PowerLime acquisition are stated after the 10:1 capital consolidation.

<sup>2</sup> Refer to ASX announcement dated 22 December 2021 for drilling results. The Company is not aware of any new information or data that materially affects the information contained in that announcement.

### **Luna Lithium, Nevada, USA**

In December 2021, Dominion invested C\$350,000 to acquire a minority stake in Luna Lithium, a private Canadian company exploring the Pilot Peak lithium brine project in Nevada, USA.

Luna Lithium has secured a land package in the region of approximately 22,000 acres and has recently completed early-stage exploration work, including geophysical and seismic surveys, and expects to commence an initial drill program in Q1 2022.

The Pilot Peak project is in close proximity to major lithium brine operations and development projects, including Albemarle's Silver Peak operation and Ioneer's Rhyolite Ridge project.

### **OPERATING RESULTS AND DIVIDENDS**

The loss after tax of the Group for the financial year ended 31 December 2021 was \$1,067,342 (2020: profit after tax \$281,991). No dividend was proposed or paid.

The significant items affecting the loss after tax were:

- i. Costs totalling \$265,685 including legal costs, ASX and share registry costs and insurance costs associated with the PowerLime acquisition and the re-compliance listing of the Company's shares on the ASX (2020: \$Nil).
- ii. Exploration expenses totalling \$200,950 incurred in relation to the exploration programs undertaken at the Georgia Lime Project (2020: \$Nil).
- iii. In the prior period the Company received a research and development tax rebate of \$667,611. No research and development rebate was received in the current year.

### **CHANGES IN ISSUED CAPITAL**

During the financial year ended 31 December 2021 the following changes occurred in the Company's issued capital

- i. On 9 September 2021 the Company completed a 10:1 capital consolidation, reducing the number of ordinary shares on issue by 938,551,613 shares.
- ii. On 27 September 2021 the Company issued 18,750,000 fully paid ordinary shares and 10,687,498 unlisted options as consideration for the acquisition of PowerLime.
- iii. On 27 September 2021 the Company issued 2,816,937 fully paid ordinary shares in settlement of accrued director remuneration.
- iv. On 27 October 2021 the Company issued 100,000,000 fully paid ordinary shares at an issue price of \$0.04 per share to raise \$4,000,000.

### **SIGNIFICANT CHANGES IN STATE OF AFFAIRS**

Other than the matters reported elsewhere in this report, there were no significant changes in the state of affairs of the Company during the financial year.

### **LIKELY DEVELOPMENTS AND EXPECTED RESULTS**

Following the success of the diamond drill program, Dominion commenced work on the preparation of a maiden mineral resource estimate for the Georgia Lime Project and appointed respected North American engineering firm Marshall Miller & Associates to commence initial technical studies.

### **ENVIRONMENTAL REGULATION AND PERFORMANCE**

The Company's operations are not subject to any significant environmental regulations under either Commonwealth or State legislation. Nonetheless, the Company is committed to high standards of environmental care.

### **UNISSUED SHARES: SHARE OPTIONS**

At the date of this report there were 16,312,498 (31 December 2020: 5,250,000) unissued ordinary shares under options as detailed in the table below. Option holders do not have any rights to participate in any issues of shares or other interests of the Company or any other entity. During the financial year ended 31 December 2021, no ordinary shares of the Company were issued on the exercise of share options granted.

<b>Grant Date</b>	<b>Expiry Date</b>	<b>Exercise Price</b>	<b>Number of Options</b>
21-Aug-17	21-Aug-22	\$1.10	25,000
17-Nov-17	17-Nov-22	\$1.10	100,000
27-Sep-2021	16-Sep-2025	\$0.12	16,187,498
			<b>16,312,498</b>



### SIGNIFICANT EVENTS AFTER THE BALANCE DATE

There have been no subsequent events that required adjustment to or disclosure in the Directors' Report or the Financial Statements of the Company for the year ended 31 December 2021.

### REMUNERATION REPORT (AUDITED)

This Remuneration Report for financial year ended 31 December 2021 outlines the remuneration arrangements for the Company in accordance with the requirements of the *Corporations Act 2001* and its regulations. This information has been audited as required by section 308(3C) of the *Corporations Act 2001*.

The Company's remuneration framework and practices are designed to align remuneration outcomes with shareholder interests and to attract and retain persons with appropriate and relevant capability. This remuneration report details the remuneration arrangements for key management personnel (KMP) who are defined as those persons having authority and responsibility for planning, directing and controlling the major activities of the Company, directly or indirectly, including any Director, whether executive or otherwise.

For the purposes of this report, the term "Director" refers to Non-executive Directors (NEDs) and Executive Directors. "KMP" refers to other key management personnel.

The names and details of the Directors and KMP of the Company in office during the financial year and until the date of this report are detailed below. Unless otherwise noted, Directors and KMP listed are in office at the date of the report. There were no changes to KMP after the Balance Date and before the date this financial report was authorised for issue.

#### Non-Executive Directors

David Brookes	Non-Executive Director and Chairman
Anastasios Arima	Non- Executive Director (appointed 1 November 2021)
John Michailidis	Non-Executive Director (resigned 1 November 2021)
Melanie Farris	Non-Executive Director (appointed 20 April 2021, resigned 1 November 2021)
Christian Behrenbruch	Non- Executive Director (resigned 28 May 2021)

#### Executive Director

Dominic Allen	Executive Director and Chief Executive Office (appointed 1 November 2021)
---------------	---

#### **Director Remuneration**

Under the Constitution, the Board may decide the remuneration from the Company to which each Director is entitled for their services as a Director of the Company. However, under the Constitution and ASX Listing Rules, the total aggregate amount provided to all non-executive Directors for their services as Directors must not exceed in any financial year the aggregate amount approved by Shareholders at the Company's general meeting. This amount is currently fixed at \$400,000 per annum.

Each Director receives an annual fee for being a Director of the Company, which reflects their obligations and responsibilities and takes into account the overall situation of the Company and its cash position. The following annual non-executive Directors' fees are agreed to be paid by the Company:

- (a) Chairman's fee: \$82,800; and
- (b) non-executive Director fee: \$59,770

The above fees paid to non-executive Directors are exclusive of statutory superannuation.

Directors do not receive additional fees for being a member of a Board committee. The remuneration of Directors must not include a commission on, or a percentage of profits or operating revenue. There are no retirement benefits.

The amount of aggregate remuneration sought to be approved by shareholders and the fees paid to Directors are reviewed annually.



### Key Management Personnel Remuneration – General Philosophy

The Company's philosophy on remuneration is that executive and key employee remuneration should be aligned with Shareholder interests by providing levels of fixed remuneration and 'at risk' pay sufficient to attract and retain individuals with the skills and experience required to build on and execute the Company's business strategy, ensuring 'at risk' remuneration is contingent on outcomes that grow and/or protect shareholder value, and aligning the interests of executives and shareholders by ensuring a suitable proportion of remuneration is received as a share-based payment.

To ensure that the Company continues to attract, retain and motivate talented staff at a competitive cost, the Company will aim to align total fixed remuneration to the median rate of the relevant market, with consideration given to experience, qualifications, performance and other non-financial benefits.

The Remuneration Committee recommends to the Board the remuneration packages for the executive team. These are reviewed annually. The Remuneration Committee may seek external advice to determine the appropriate level and structure of the remuneration packages.

Remuneration consists of:

- total fixed remuneration – base salary and superannuation; and
- 'at risk' remuneration – short-term incentives (STI) and long-term incentives (LTI).

To ensure that the Company continues to attract, retain and motivate talented staff at a competitive cost, Dominion will:

- aim to align total fixed remuneration to the median rate of the relevant market, with consideration given to experience, qualifications, performance and other non-financial benefits; and
- ensure 'at risk' remuneration provides an incentive for performance aligned with the strategic objectives of the Company.

Adjustments to fixed remuneration and 'at risk' remuneration will be paid/issued following the annual performance and remuneration review, which is conducted by executive management based on achievement against the KPIs and recommended to the Remuneration Committee; a review by the Remuneration Committee and recommendation to the Board; and approval by the Board.

Calculation of STI awards is based on achievement of KPIs set at the beginning of each year.

LTIs are offered to incentivise, reward and retain personnel, and to further align the interests of personnel and shareholders. The terms of any LTI grant are determined by the Board. LTI grants normally take the form of the issue of unlisted share options. Share options are normally issued under the company's employee share option plan (ESOP). All grants of equity are determined by the Board, following a recommendation from the Remuneration Committee.

*Executive Director – Dominic Allen*

The Company has entered into a consultancy contract with Dominic Allen to provide Chief Executive Officer services to Dominion on the following terms:

Condition	Description
Term	Commencing 1 November 2021 for a period of 24 months
Base fee	\$120,000 per annum inclusive of statutory superannuation and exclusive of GST
Short term incentive (STI)	Up to 20% of base salary based on achievement of objectives and KPIs set by the Board
Other benefits	Nil
Termination	Three months notice by either party. No additional termination benefits.
Restraints	Nil

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)**  
**DIRECTORS' REPORT**  
**31 DECEMBER 2021**

**Remuneration year ended 31 December 2021**

	Director Fees / Salaries	Super	Other fees	Share Based Payments	Total	STI	LTI
	\$	\$	\$	\$	\$	%	%
<b>Directors</b>							
D Brookes <sup>(i)</sup>	82,800	8,263	-	6,800	97,863	-	-
D Allen <sup>(ii)</sup>	22,000	-	-	-	22,000	-	-
A Arima <sup>(iii)</sup>	10,958	-	-	-	10,958	-	-
J Michailidis <sup>(i)(iii)</sup>	49,809	4,968	-	-	54,777	-	-
M Farris <sup>(i)(iv)(v)</sup>	31,422	-	37,895	-	69,317	-	-
C Behrenbruch <sup>(vi)</sup>	27,271	-	-	-	27,271	-	-
<b>Total</b>	<b>224,260</b>	<b>13,231</b>	<b>37,895</b>	<b>6,800</b>	<b>282,186</b>		

(i) For the period 1 January 2021 to 31 August 2021, 50% of non-executive directors' fees were deferred and settled via the issue of shares in lieu of cash remuneration on 27 September 2021. The amounts listed above reflect the full amount paid for the year ended 31 December 2021.

(ii) Appointed 1 November 2021.

(iii) Resigned 1 November 2021.

(iv) Appointed 20 April 2021, resigned 1 November 2021.

(v) In addition to Director fees, Melanie Farris received fees for providing Company Secretarial and consulting services to the Company pursuant to an agreement entered into between New Cavendish Pty Ltd and the Company.

(vi) Resigned 28 May 2021.

**Remuneration for the year ended 31 December 2020**

	Salaries/ Fees	Super	Share Based Payments	STI (cash)	LTI (options) <sup>(iii)</sup>	Total	STI	LTI
	\$	\$	\$	\$	\$	\$	%	%
<b>Directors<sup>(i)</sup></b>								
C Hirst <sup>(ii)</sup>	23,333	2,217	-	-	-	25,550	-	-
C Behrenbruch	46,434	-	-	-	13	46,447	-	0%
J Michailidis	42,405	4,028	-	-	971	47,404	-	2%
D Brookes	52,000	4,940	-	-	-	56,940	-	-
<b>Total</b>	<b>164,172</b>	<b>11,185</b>	<b>-</b>	<b>-</b>	<b>984</b>	<b>176,341</b>		

(i) For the period 1 August 2020 to 31 December 2020, 50% of non-executive directors' fees were deferred. The amounts listed above reflect the full amount paid and owing (as deferred fees) for the year ended 31 December 2020. The total amount owing to directors as deferred fees at 31 December 2020 was as follows: D Brookes \$18,889; C Behrenbruch \$13,635; J Michailidis \$13,635.

(ii) Resigned 30 July 2020.

(iii) Options expense relates to sign-on options or options issued in lieu of director fees issued in prior years. Options for C Behrenbruch were issued 1 July 2016; options for J Michailidis were issued 1 November 2017.

Shareholdings of Directors and KMP for the year ended 31 December 2021

	Balance 1 January 2021	Share consolidation	Received in lieu of cash remuneration	Net Acquired /(Disposed)	Held at time of appointment / (resignation)	Balance 31 December 2021
D Brookes	12,800,000	(11,520,000)	1,121,250	2,500,000	-	4,901,250
D Allen <sup>(i)</sup>	-	-	-	-	2,410,624	2,410,624
A Arima <sup>(i)</sup>	-	-	-	-	910,624	910,624
J Michailidis <sup>(ii)</sup>	527,432	(474,688)	809,399	-	(862,143)	-
M Farris <sup>(ii)(iii)</sup>	-	-	204,525	-	(204,525)	-
C Behrenbruch <sup>(iv)</sup>	3,265,306	(2,938,775)	-	-	(326,531)	-
<b>Total</b>	<b>16,592,738</b>	<b>(14,933,463)</b>	<b>2,135,174</b>	<b>2,500,000</b>	<b>1,928,049</b>	<b>8,222,498</b>

- (i) Appointed 1 November 2021  
 (ii) Resigned 1 November 2021  
 (iii) Appointed 20 April 2021  
 (iv) Resigned 28 May 2021

Option Holdings of Directors and KMP for the year ended 31 December 2021

	Balance 1 January	Share consolidation	Options granted	Lapsed	Held at time of appointment / (resignation)	Balance 31 December	Vested 31 and exercisable December
D Brookes	-	-	500,000	-	-	500,000	500,000
D Allen <sup>(i)</sup>	-	-	-	-	1,303,541	1,303,541	1,303,541
A Arima <sup>(i)</sup>	-	-	-	-	1,303,541	1,303,541	1,303,541
J Michailidis <sup>(ii)</sup>	1,000,000	(900,000)	-	-	(100,000)	-	-
M Farris <sup>(ii)(iii)</sup>	-	-	-	-	25,000 (25,000)	-	-
C Behrenbruch <sup>(iv)</sup>	3,000,000	-	-	(3,000,000)	-	-	-
<b>Total</b>	<b>4,000,000</b>	<b>(900,000)</b>	<b>500,000</b>	<b>(3,000,000)</b>	<b>2,507,082</b>	<b>3,107,082</b>	<b>3,107,082</b>

- (i) Appointed 1 November 2021  
 (ii) Resigned 1 November 2021  
 (iii) Appointed 20 April 2021  
 (iv) Resigned 28 May 2021

Related Party Transactions with KMP

Remuneration: Remuneration to KMP is recorded in the tables above.

Loans: There were no loans between the Company and any KMP in the year ended 31 December 2021.

Other transactions: The Company entered into an agreement with New Cavendish Pty Ltd, which is a consulting company of Non-Executive Director, Ms Melanie Farris. The consulting agreement is for services associated with Company Secretarial and consultancy services. Amounts paid to New Cavendish Pty Ltd during the period that Ms Farris was a KMP are included in the remuneration tables above.

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)**  
**DIRECTORS' REPORT**  
**31 DECEMBER 2021**

Other than those noted above, there were no related party transactions with any KMP in the year ended 31 December 2021.

**Grants of options affecting remuneration**

The terms and conditions of each grant of options affecting remuneration in the current or a future reporting period are as follows:

Date of grant	Vesting date	Expiry date	Exercise price	Value per option at grant date	Number granted	Vested
1 November 2021	1 November 2021	31 October 2025	\$0.12	\$0.0136	500,000	500,000

When exercisable, each option is convertible into one ordinary share of Dominion Minerals Limited.

Options are granted to attract, retain, and incentivise key management personnel.

The board has rules that contain restrictions on removing the 'at risk' aspect of the options granted to executives. Executives may not enter into any transactions designed to remove the 'at risk' aspect of an instrument before it vests.

**Remuneration, Group performance and shareholder wealth**

The development of remuneration policies and structures is considered in relation to the effect on Group performance and shareholder wealth. They are designed by the Board to align Director and Executive behaviour with improving Group performance and ultimately shareholder wealth.

Executives are currently remunerated by a combination of cash base remuneration and options. The options granted are considered by the Board to provide an alignment between the employees and shareholders interests.

The table below shows for the current financial year and previous four financial years the total remuneration cost of the key management personnel, earnings per ordinary share (EPS), dividends paid or declared, and the closing price of ordinary shares on ASX at year end.

Financial Year	Total Remuneration \$	EPS (Cents) <sup>1</sup>	Dividends (Cents)	Share Price (Cents) <sup>1</sup>
2021	284,538	(0.84)	-	6.4
2020	176,341	0.3	-	5.0
2019	87,712	1.6	-	3.0
2018	1,304,385	(0.136)	-	2.0
2017	1,062,477	(0.098)	-	50.6

<sup>1</sup> EPS and share price data for all years has been adjusted to reflect the 10:1 capital consolidation completed in the 2021 financial year.

Given the stage of the Company's development and the fact that it does not currently have any revenue producing operations, the Board does not consider EPS or dividends paid or declared to be meaningful measures for assessing executive performance.

**Voting and comments made at the Company's 2020 Annual General Meeting**

The Company received more than 90% of "yes" votes on its remuneration report for the financial year ended 31 December 2020. The Company did not receive any specific feedback at the AGM or throughout the year on its remuneration practices.

**END OF REMUNERATION REPORT**

**INDEMNITY**

Subject to the Corporations Act and the Constitution of the Company, the Company must indemnify each Director, Company Secretary and Executive Officer to the maximum extent permitted by law, against any liability incurred by them as, or by virtue of their holding office as and acting in the capacity of Director, Company Secretary or Executive Officer of the Company. Insurance premiums have been paid during the period in respect of a contract insuring

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)**  
**DIRECTORS' REPORT**  
**31 DECEMBER 2021**

Directors and Officers against legal costs incurred in defending proceedings against them. Details of the nature of liabilities covered or the amount of premiums paid are not disclosed as such disclosure is prohibited in the terms of the contract.

**SCHEDULE OF MINING TENEMENTS**

As at 31 December 2021, Dominion did not have an ownership interest in any mineral exploration tenements. The Company's 100% owned U.S. subsidiary, PowerLime, Inc has an option to purchase the Georgia Lime Project in southwest Georgia, USA.

**PROCEEDINGS ON BEHALF OF THE GROUP**

The Group is not aware that any person has applied to the court under section 237 of the Corporations Act 2001 for leave to bring proceedings on behalf of the Group, or to intervene in any proceedings in which the Group is a party, for the purpose of taking responsibility on behalf of the Group for all or part of those proceedings.

No proceedings have been brought or intervened in on behalf of the Group with leave of the court under section 237 of the Corporations Act 2001.

**NON-AUDIT SERVICES**

The Group may decide to employ the auditor on assignments additional to their statutory audit duties where the auditor's expertise and experience with the Group and/or the Group are important. During the financial year the Group paid \$25,000 to the auditors for the preparation of an Investigating Accountant's Report for inclusion in the Company's Prospectus dated 9 September 2021 (2020: none).

Details of the amounts paid or payable to the auditor, PKF Brisbane Audit for audit and non-audit services provided during the year are set out in Note 27 to the financial report.

**AUDITOR INDEPENDENCE AND NON-AUDIT SERVICES**

A statement of independence has been provided by the Company's auditor, PKF Brisbane Audit, and is attached to this Directors' Report as required by section 307C of the *Corporations Act 2001*.

**ROUNDING OF AMOUNTS IN ACCORDANCE WITH ASIC CORPORATIONS (ROUNDING IN FINANCIAL / DIRECTORS' REPORTS) INSTRUMENT 2016/191**

The amounts in the Directors' report and in the financial report have been rounded to the nearest dollar. This report is made in accordance with a resolution of directors.

Signed in accordance with a resolution of the Directors



**Dr David Brookes**

**Chairman**

**29 March 2022**

AUDITOR'S INDEPENDENCE DECLARATION  
UNDER SECTION 307C OF THE CORPORATIONS ACT 2001  
TO THE DIRECTORS OF DOMINION MINERALS LIMITED

I declare that, to the best of my knowledge and belief, during the year ended 31 December 2021, there have been no contraventions of:

- (a) the auditor independence requirements of the *Corporations Act 2001* in relation to the audit; and
- (b) any applicable code of professional conduct in relation to the audit.

This declaration is in respect of Dominion Minerals Limited and the entities it controlled during the year.

*PKF*

PKF BRISBANE AUDIT



LIAM MURPHY  
PARTNER

BRISBANE  
29 MARCH 2022

For personal use only

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)**  
**CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

	Note	2021 \$	2020 \$
<b>Continuing operations</b>			
Interest received		5,612	5,199
Other income	6	-	21,528
Total revenue		5,612	26,727
<b>Research and development operations</b>			
- Clinical trials expenses	7	-	191,331
- Intellectual property		-	(3,922)
- Research and development tax rebate	16(a)	-	667,611
		-	855,020
<b>Corporate and Administration expenses</b>			
- ASX and share registry		(103,409)	(52,468)
- Legal and compliance costs		(112,792)	(152,414)
- Director remuneration		(245,672)	(175,978)
- Consultants		(64,241)	(67,364)
- Administration expenses		(108,034)	(108,312)
- Share based payment expense		(6,800)	(1,874)
- Impairment expense – trade receivables		51,936	-
- Corporate transaction costs		(265,685)	(35,010)
- Finance costs		(1,197)	(287)
- Gains / (losses) on foreign exchange	8	(16,110)	(6,048)
		(872,002)	(599,756)
<b>Georgia Lime Project expenses</b>			
- Metallurgical test work and assaying costs		(25,892)	-
- Drilling costs		(72,983)	-
- Geological consultants		(102,075)	-
		(200,950)	-
Profit / (loss) before income tax		(1,067,342)	281,991
Income tax expense	16(a)	-	-
Net profit / (loss) from continuing operations		(1,067,342)	281,991
<b>Other comprehensive income / (loss)</b>			
<b>Items that may be reclassified to the profit or loss</b>			
Exchange differences on translation of foreign operations	18(b)	(765)	-
Other comprehensive income / (loss) for the year		(765)	-
Net profit / (loss) attributable to members of the Group		(1,067,342)	281,991
Total comprehensive income / (loss) attributable to members of the Group		(1,068,107)	281,991

*The accompanying notes form part of these financial statements.*



DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
CONSOLIDATED STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME  
FOR THE YEAR ENDED 31 DECEMBER 2021

<b>Earnings per share for loss attributable to the ordinary equity holders of the Group:</b>		<b>Cents</b>	<b>cents</b>
Basic earnings per share	27	(0.84)	0.30
Diluted earnings per share	27	(0.84)	0.30

*The accompanying notes form part of these financial statements.*

For personal use only

DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
CONSOLIDATED STATEMENT OF FINANCIAL POSITION  
AS AT 31 DECEMBER 2021

	Note	2021 \$	2020 \$
<b>CURRENT ASSETS</b>			
Cash and cash equivalents	9	4,909,553	3,199,739
Trade and other receivables	10	666	11,860
Financial assets at fair value	11	1,256,162	-
Other assets	12	228,009	45,150
<b>TOTAL CURRENT ASSETS</b>		<b>6,394,390</b>	<b>3,256,749</b>
<b>NON-CURRENT ASSETS</b>			
Other assets	12	94,137	-
Investments in financial assets	13	388,547	-
Intangible assets	14	10,867	-
<b>TOTAL NON-CURRENT ASSETS</b>		<b>493,551</b>	<b>-</b>
<b>TOTAL ASSETS</b>		<b>6,887,941</b>	<b>3,256,749</b>
<b>CURRENT LIABILITIES</b>			
Trade and other payables	15	164,490	84,469
<b>TOTAL CURRENT LIABILITIES</b>		<b>164,490</b>	<b>84,469</b>
<b>TOTAL LIABILITIES</b>		<b>164,490</b>	<b>84,469</b>
<b>NET ASSETS</b>		<b>6,723,451</b>	<b>3,172,280</b>
<b>EQUITY</b>			
Contributed equity	17	88,632,867	84,213,601
Reserves	18	258,585	126,790
Accumulated losses		(82,168,001)	(81,168,111)
<b>TOTAL EQUITY</b>		<b>6,723,451</b>	<b>3,172,280</b>

*The accompanying notes form part of these financial statements.*

DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
FOR THE YEAR ENDED 31 DECEMBER 2021

	Share Capital \$	Option Reserve \$	Foreign Exchange Translation Reserve \$	Accumulated Losses \$	Total \$
<b>Balance at 1 January 2021</b>	<b>84,213,601</b>	<b>126,790</b>	<b>-</b>	<b>(81,168,111)</b>	<b>3,172,280</b>
Comprehensive income:					
- Loss for the year	-	-	-	(1,067,342)	(1,067,342)
- Foreign currency translation difference	-	-	(765)	-	(765)
Total comprehensive income for the year	-	-	(765)	(1,067,342)	(1,068,107)
Transactions with owners in their capacity as owners:					
- Issue of equity securities	4,862,677	200,012	-	-	5,062,689
- Transaction costs	(443,411)	-	-	-	(443,411)
- Option reserve lapsed/expired	-	(67,452)	-	67,452	-
Total transactions with owners	4,419,266	132,560	-	67,452	4,619,278
<b>Balance at 31 December 2021</b>	<b>88,632,867</b>	<b>259,350</b>	<b>(765)</b>	<b>(82,168,001)</b>	<b>6,723,451</b>
<b>Balance at 1 January 2020</b>	<b>84,213,601</b>	<b>208,181</b>	<b>-</b>	<b>(81,533,367)</b>	<b>2,888,415</b>
Comprehensive income:					
- Profit for the year	-	-	-	281,991	281,991
Total comprehensive income for the year	-	-	-	281,991	281,991
Transactions with owners in their capacity as owners:					
- Share option expense	-	1,874	-	-	1,874
- Option reserve lapsed/expired	-	(83,265)	-	83,265	-
Total transactions with owners	-	(81,391)	-	83,265	1,874
<b>Balance at 31 December 2020</b>	<b>84,213,601</b>	<b>126,790</b>	<b>-</b>	<b>(81,168,111)</b>	<b>3,172,280</b>

The accompanying notes form part of these financial statements.

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)**  
**THE CONSOLIDATED STATEMENT OF CASH FLOWS**  
**FOR THE YEAR ENDED 31 DECEMBER 2021**

	Note	2021 \$	2020 \$
<b>CASH FLOW FROM OPERATING ACTIVITIES</b>			
Government grants		-	21,528
Payments to suppliers and employees		(985,029)	(492,667)
Payment of preliminary transaction costs (Longmile)		-	(35,010)
Interest received		5,612	5,199
R&D tax rebate received		-	667,611
Net cash provided by/ (used in) operating activities	26(b)	<b>(979,417)</b>	<b>166,661</b>
<b>CASH FLOW FROM INVESTING ACTIVITIES</b>			
Payments for property, plant and equipment		(11,506)	-
Payments for options		(517,305)	-
Payments for Investments in unlisted companies		(388,547)	-
Net cash provided by/ (used in) investing activities		<b>(917,358)</b>	-
<b>CASH FLOW FROM FINANCING ACTIVITIES</b>			
Proceeds from issue of shares		4,000,000	-
Costs of share issue		(393,411)	-
Net cash provided by/ (used in) financing activities		<b>3,606,589</b>	-
Net increase / (decrease) in cash held		1,709,814	166,661
Cash and cash equivalents at beginning of year		3,199,739	3,038,810
Effects of exchange rate fluctuations on cash and cash equivalents		-	(5,732)
<b>Cash and cash equivalents at end of year</b>	26(a)	<b>4,909,553</b>	<b>3,199,739</b>

*The accompanying notes form part of these financial statements.*

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
NOTES TO THE FINANCIAL STATEMENTS**

**1. GENERAL INFORMATION**

Dominion Minerals Limited (formerly Factor Therapeutics Limited) ("Dominion" or "Company") is a public company limited by shares incorporated in Australia whose shares were listed on the Australian Securities Exchange on 19 March 2004 (ASX: DLM).

On 27 September 2021, the Company completed the acquisition of PowerLime Inc at which time the business on the Company changed to that of mineral exploration activities.

**2. APPLICATION OF NEW AND REVISED ACCOUNTING STANDARDS**

The Company has adopted all of the new and revised Standards and Interpretations issued by the Australian Accounting Standards Board (the AASB) that are relevant to its operations and effective for the current year. The adoption of these new and revised accounting standards and interpretations did not have any material effect on the financial results or financial position of the Group or the Company for the reporting period.

The Directors do not consider that the adoption of any new standards and Interpretations in issue but not yet effective at the date of these financial statements will have a material impact on the financial statements of the Group.

**3. CHANGES IN ACCOUNTING POLICIES**

On 27 September 2021, the Company completed the acquisition of PowerLime Inc at which time the business on the Company changed to that of mineral exploration activities, resulting in the need to consider and / or adopt new accounting policies. Significant new accounting policies adopted by the group are outlined below.

**a. Subsidiaries**

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity.

In the Company's statement of financial position, investments in subsidiaries are accounted for at cost less accumulated impairment losses. On disposal of the investments, the difference between disposal proceeds and the carrying amount of the investments are recognised in profit or loss.

**b. Basis of consolidation**

The consolidated financial statements incorporate the assets and liabilities of all subsidiaries of the Company as at 31 December 2021 and the results of all subsidiaries for the year then ended. The Company and its subsidiaries together are referred to in this financial report as the Group or the Group.

Subsidiaries are all entities over which the Group has control. The Group controls an entity when the Group is exposed to, or has rights to, variable returns from its involvement with the entity and has the ability to affect those returns through its power to direct the activities of the entity.

Subsidiaries are fully consolidated from the date on which control is transferred to the Group. They are de-consolidated from the date that control ceases. The acquisition method of accounting is used to account for the acquisition of subsidiaries by the Group. Intercompany transactions, balances and unrealised gains on transactions between Group companies are eliminated. Unrealised losses are also eliminated unless the transaction provides evidence of the impairment of the asset transferred. Accounting policies of subsidiaries have been changed where necessary to ensure consistency with the policies adopted by the Group.

**3. CHANGES IN ACCOUNTING POLICIES (continued)**

**c. Foreign currency**

*Functional and presentation currency*

Items included in the financial statements of each entity in the Group are measured using the currency of the primary economic environment in which the entity operates ("the functional currency"). The financial statements of the Group are presented in Australian, which is the Company's functional and presentation currency.

*Transactions and balances*

Transactions in a currency other than the functional currency ("foreign currency") are translated into the functional currency using the exchange rates prevailing at the dates of the transactions. Currency translation gains and losses resulting from the settlement of such transactions and from the translation at year-end exchange rates of monetary assets and liabilities denominated in foreign currencies are recognised in profit or loss, except for currency translation differences on net investment in foreign operations and borrowings and other currency instruments qualifying as net investment hedges for foreign operations, which are included in the currency transaction reserve within equity in the consolidated financial statements.

Non-monetary items measured at fair values in foreign currencies are translated using the exchange rates at the date when the fair values are determined.

*Translation of group entities' financial statements*

The results and financial position of all group entities (none of which has the currency of a hyperinflationary economy) that have a functional currency different from the Company's presentation currency are translated into the presentation currency as follows:

- (i) Assets and liabilities are translated at the closing rates at the date of the Statement of Financial Position.
- (ii) Income and expenses are translated at average exchange rates (unless the average is not a reasonable approximation of the cumulative effect of the rates prevailing on the transaction dates, in which case income and expenses are translated using the exchange rates at the dates of the transactions); and
- (iii) All resulting exchange differences are recognised in the currency translation reserve within equity.

On consolidation, exchange differences arising from the translation of the net investment in foreign operations (including monetary items that, in substance, form part of the net investment in foreign entities), and of borrowings and other currency instruments designated as hedges of such investments, are taken to the foreign currency translation reserve.

On disposal of a foreign group entity, the cumulative amount of the currency translation reserve relating to that foreign entity is reclassified from equity and recognised in profit or loss when the gain or loss on disposal is recognised.

**d. Exploration and evaluation expenditure**

Exploration and evaluation costs, including the costs of acquiring licences, are capitalised as exploration and evaluation assets on an area of interest basis. Costs incurred before the Company has obtained legal rights to explore an area are expensed in the profit or loss.

Exploration and evaluation assets are only recognised if the rights to the area of interest are current and either:

- (i) the expenditures are expected to be recouped through successful development and exploitation of the area of interest or by its sale; or

### 3. CHANGES IN ACCOUNTING POLICIES (continued)

- (ii) activities in the area of interest have not, at the reporting date, reached a stage which permits a reasonable assessment of the existence or otherwise of economically recoverable reserves, and active and significant operations in, or in relation to, the area of interest are continuing.

Exploration and evaluation assets are assessed for impairment if sufficient data exists to determine technical feasibility and commercial viability and the facts and circumstances suggest that the carrying amount exceeds the recoverable amount. For the purposes of impairment testing, exploration and evaluation assets are allocated to cash-generating units to which the exploration activity relates. The cash-generating unit shall not be larger than the area of interest.

Once technical feasibility and commercial viability of the area of interest are demonstrable, exploration and evaluation assets attributable to that area are first tested for impairment and then reclassified from exploration and evaluation assets to property and development assets within property, plant, and equipment.

### 4. SIGNIFICANT ACCOUNTING POLICIES

#### a. Statement of compliance

The financial statements comprise the consolidated financial statements of the Group consisting of Dominion Minerals Limited and its subsidiaries. The Group is a for-profit entity for the purpose of preparing the financial statements.

This financial report is a general purpose financial report that has been prepared in accordance with Australian Accounting Standards, including Australian Accounting Interpretations, other authoritative pronouncements of the Australian Accounting Standards Board and the *Corporations Act 2001*. The Group is a for-profit entity for financial reporting purposes under Australian Accounting Standards.

Except for cash flow information, the financial report has been prepared on an accruals basis, based on historical costs, modified, where applicable, by the measurement at fair value of selected non-current assets, financial assets and financial liabilities.

The financial report was authorised for issue on 29 March 2022.

#### b. Going concern

The financial statements have been prepared on a going concern basis, which contemplates continuity of normal business activities and the realisation of assets and settlement of liabilities in the normal course of business.

The Group incurred a loss for the year ended 31 December 2021 of \$1,067,342 (2020 profit: \$281,991), net cash outflows from operating activities of \$979,417 (2020: \$166,601 inflows) and net outflows from investing activities of \$917,358 (2020: \$Nil).

During the year the Group was successful at raising capital and at 31 December 2021 had cash and cash equivalents of \$4,909,553 (2020: \$3,199,739). As at 31 December 2021 the Group had net working capital of \$6,229,900 (2020 \$3,172,280) and net assets of \$6,723,451 (2020: \$3,172,280).

The ability of the Group to continue as a going concern is principally dependent upon the Group managing its cash reserves in order to balance the execution of its exploration and development strategy with maintaining adequate working capital reserves.

Having carefully assessed the Group's forecasts and its ability to effectively manage expenditures and cash flows from operations, the Directors believe that the Group's existing cash reserves are adequate to fund the Group's committed expenditures for at least 12 months from the date of this report and that there is a reasonable basis to prepare the financial statements on a going concern basis.



#### 4. SIGNIFICANT ACCOUNTING POLICIES (continued)

##### c. Basis of preparation

The consolidated general purpose financial statements have been prepared on the basis of historical cost, except for certain financial instruments that are measured at revalued amounts or fair values at the end of each reporting period, as explained in the accounting policies below. Historical cost is generally based on the fair values of the consideration given in exchange for goods and services. All amounts are presented in Australian dollars, unless otherwise noted. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date, regardless of whether that price is directly observable or estimated using another valuation technique. In estimating the fair value of an asset or liability, the Group takes into account the characteristics of the asset or liability if market participants would take those characteristics into account when pricing the asset or liability at the measurement date. Fair value for measurement and/or disclosure purposes in these consolidated financial statements is determined on such a basis, except for share-based payment transactions that are within the scope of AASB2 and measurements that have some similarities to fair value but are not fair value such as value in use in AASB 136.

In addition, for financial reporting purposes, fair value measurements are categorised into Level 1, 2 or 3 based on the degree to which the inputs to the fair value measurement are observable and the significance of the inputs to the fair value measurement in its entirety, which are described as follows:

- Level 1 inputs are quoted prices (unadjusted) in active markets for identical assets or liabilities that the entity can access at the measurement date.
- Level 2 inputs are inputs, other than quoted prices included within Level 1, that are observable for the asset or liability, either directly or indirectly; and
- Level 3 inputs are unobservable inputs for the asset or liability.

The principal accounting policies are set out below.

##### d. Income Tax

The income tax expense (income) for the year comprises current income tax expense (income) and deferred tax expense (income). Current income tax expense (income) charged to the profit or loss is the tax payable on taxable income calculated using applicable income tax rates enacted, or substantially enacted, as at reporting date. Current tax liabilities (assets) are measured at the amounts expected to be paid to (recovered from) the relevant taxation authority.

Deferred income tax expense reflects movements in deferred tax asset and deferred tax liability balances during the year as well unused tax losses.

Current and deferred income tax expense (income) is charged or credited directly to equity instead of the profit or loss when the tax relates to items that are credited or charged directly to equity.

Deferred tax assets and liabilities are ascertained based on temporary differences arising between the tax bases of assets and liabilities and their carrying amounts in the financial statements. Deferred tax assets also result where amounts have been fully expensed but future tax deductions are available. No deferred income tax will be recognised from the initial recognition of an asset or liability, excluding a business combination, where there is no effect on accounting or taxable profit or loss.

Deferred tax assets and liabilities are calculated at the tax rates that are expected to apply to the period when the asset is realised or the liability is settled, based on tax rates enacted or substantively enacted at reporting date. Their measurement also reflects the manner in which management expects to recover or settle the carrying amount of the related asset or liability.

**4. SIGNIFICANT ACCOUNTING POLICIES (continued)**

Deferred tax assets relating to temporary differences and unused tax losses are recognised only to the extent that it is probable that future taxable profit will be available against which the benefits of the deferred tax asset can be utilised.

**e. Research and Development expenditure**

Expenditure during the research phase of a project is recognised as an expense when incurred. Development costs are capitalised only when technical feasibility studies identify that the project will deliver future economic benefits and these benefits can be measured reliably.

The Group has adopted the profit and loss approach to accounting for research and development tax offsets under the revised regime, pursuant to *AASB 120 Accounting for Government Grant and Disclosure of Government Assistance*. Under this approach the grant or incentive is recorded as part of revenue in the profit and loss.

**f. Intangibles**

*Licenses, Patents and Intellectual Property*

Licenses and patents are recognised at cost of acquisition. They have a finite life and are carried at cost less any accumulated amortisation and any impairment losses. Licenses and patents are amortised over their useful life, which has been assessed as ten years from the date the intangible asset is in its intended use.

**g. Employee benefits**

Provision is made for the Group's liability for employee benefits arising from services rendered by employees to balance date. Employee benefits that are expected to be settled within one year have been measured at the amounts expected to be paid when the liability is settled, plus related on-costs.

Employee benefits payable later than one year have been measured at the present value of the estimated future cash outflows to be made for those benefits with consideration given to employees' wages increases and the probability that the employees may satisfy vesting requirements. Those cash flows are discounted using market yields on corporate bonds with terms to maturity that match the expected timing of cash flows attributable to employee benefits.

**h. Share based compensation**

The Group makes equity-settled share-based payments to directors, employees and other parties for services provided to the Group. Where applicable, the fair value of the equity is measured at grant date and recognised as an expense over the vesting period, with a corresponding increase to an equity account. The fair value of shares is ascertained as the market bid price. The fair value of options is ascertained using the Black Scholes option valuation pricing model which incorporates all market vesting conditions. Where applicable, the number of shares and options expected to vest is reviewed and adjusted at each reporting date such that the amount recognised for services received as consideration for the equity instruments granted shall be based on the number of equity instruments that eventually vest.

Where the fair value of services rendered by other parties can be reliably determined, this is used to measure the equity-settled payment.

**i. Cash and cash equivalents**

Cash and cash equivalents include cash on hand, deposits held at call with banks, other short-term highly liquid investments, and bank overdrafts.

4. **SIGNIFICANT ACCOUNTING POLICIES (continued)**

j. **Financial assets**

*Recognition and derecognition*

Regular purchases and sales of financial assets are recognised on trade-date which is, the date on which the Group commits to purchase or sell the asset. Financial assets are derecognised when the rights to receive cash flows from the financial assets have expired or have been transferred and the Group has transferred substantially all risks and rewards of ownership.

Financial assets are initially measured at fair value. Transaction costs that are directly attributable to the acquisition of financial assets (other than financial assets at fair value through profit or loss) are added to the fair value of the financial assets on initial recognition. Transaction costs directly attributable to acquisition of financial assets at fair value through profit or loss are recognised immediately in profit or loss.

**Financial assets at fair value through other comprehensive income**

Financial assets at fair value through other comprehensive income include equity investments which the Group intends to hold for the foreseeable future and has irrevocably elected to classify them as such upon initial recognition.

*Classification and measurement*

All financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets. The Group classifies its financial assets based on the Group's business model for managing the financial asset and the contractual cash flow characteristics of the financial assets. The Group's financial assets are classified at amortised cost which comprise other receivables and cash and cash equivalents.

Financial assets at amortised cost are subsequently measured using the effective interest rate (EIR) method and are subject to impairment. Gains and losses are recognised in profit or loss when the asset is derecognised, modified, or impaired. Interest income from these financial assets is included in interest income using the EIR method.

*Impairment*

The Group recognises an allowance for expected credit losses ("ECLs") for financial assets carried at amortised cost. ECLs are based on the difference between the contractual cash flows due in accordance with the contract and all the cash flows that the Group expects to receive, discounted at an approximation of the original effective interest rate.

The Group recognises an impairment gain or loss in profit or loss for all financial assets with a corresponding adjustment to their carrying amount through a loss allowance account.

*Offsetting of financial assets and financial liabilities*

Financial assets and liabilities are offset, and the net amount presented on the balance sheet when, and only when the Group has a legal right to offset the amounts and intends either to settle on a net basis or to realise the asset and settle the liability simultaneously.

k. **Financial liabilities**

Financial liabilities include trade and other payables. Financial liabilities are recognised on the balance sheet when, and only when, the Group becomes a party to the contractual provisions of the financial instruments. Financial liabilities are initially recognised at fair value plus directly attributable transaction costs and subsequently measured at amortised cost, comprising original debt less principal payments and amortisation

For personal use only

4. SIGNIFICANT ACCOUNTING POLICIES (continued)

A financial liability is derecognised when the obligation under the liability is extinguished. Gains and losses are recognised in profit or loss when the liabilities are derecognised and through the amortisation process. Financial liabilities are classified as current liabilities unless the Group has an unconditional right to defer settlement of the liability for at least twelve months after the reporting period.

**i. Trade receivables**

Trade receivables are initially recognised at fair value and subsequently measured at amortised cost using the effective interest method, less any allowance for expected credit losses. Other receivables are recognised at amortised cost, less any allowance for expected credit losses.

**m. Revenue recognition**

Revenues are recognised at fair value of the consideration received net of any applicable taxes.

Interest revenue is recognised as it accrues taking into account the interest rates applicable to the financial assets.

Government grants are recognised at fair value where there is reasonable assurance that the grant will be received, and all grant conditions will be met. Grants relating to expense items are recognised as income over the periods necessary to match the grant to the costs they are compensating. Grants relating to assets are credited to deferred income at fair value and are credited to income over the expected useful life of the asset on a straight-line basis.

All revenue is stated net of the amount of goods and services tax.

**n. Goods and Services Tax (GST)**

Revenues, expenses and assets are recognised net of the amount of GST, except where the amount of GST incurred is not recoverable from the Australian Taxation Office. In these circumstances the GST is recognised as part of the cost of acquisition of the asset or as part of an item of the expense. Receivables and payables in the statement of financial position are shown inclusive of GST. The net amount of GST recoverable from, or payable to, the ATO is included in other receivables or payables in the Statement of Financial Position. Cash flows are presented in the statement of cash flows on a gross basis, except for the GST component of investing and financing activities, which are disclosed as operating cash flows.

**o. Property, plant and equipment**

Each class of property, plant and equipment is carried at cost or fair value less, where applicable, any accumulated depreciation and impairment losses.

*Plant and equipment*

Plant and equipment are measured on the cost basis and therefore carried at cost less accumulated depreciation and any accumulated impairment. In the event the carrying amount of plant and equipment is greater than the estimated recoverable amount, the carrying amount is written down immediately to the estimated recoverable amount and impairment losses are recognised either in profit or loss or as a revaluation decrease if the impairment losses relate to a revalued asset. A formal assessment of recoverable amount is made when impairment indicators are present (refer to Note 4(q) for details of impairment).

**4. SIGNIFICANT ACCOUNTING POLICIES (continued)**

The carrying amount of plant and equipment is reviewed annually by Directors to ensure it is not in excess of the recoverable amount from these assets. The recoverable amount is assessed on the basis of the expected net cash flows that will be received from the asset's employment and subsequent disposal. The expected net cash flows have been discounted to their present values in determining recoverable amounts.

Subsequent costs are included in the asset's carrying amount or recognised as a separate asset, as appropriate, only when it is probable that future economic benefits associated with the item will flow to the Group and the cost of the item can be measured reliably. All other repairs and maintenance are charged to the Consolidated Statement of Profit or Loss and Other Comprehensive Income during the financial period in which they are incurred.

*Depreciation*

The depreciable amount of all fixed assets including building and capitalised lease assets, but excluding freehold land, is depreciated on a straight-line basis over their useful lives to the Group commencing from the time the asset is held ready for use. The expected useful life for plant and equipment is 3 to 10 years.

The assets' residual values and useful lives are reviewed, and adjusted if appropriate, at the end of each reporting period. An asset's carrying amount is written down immediately to its recoverable amount if the asset's carrying amount is greater than its estimated recoverable amount. Gains and losses on disposals are determined by comparing proceeds with the carrying amount. These gains and losses are included in the Consolidated Statement of Profit or Loss and Other Comprehensive Income. When revalued assets are sold, amounts included in the revaluation reserve relating to that asset are transferred to retained earnings.

**p. Leases**

Trade and other payables represent liabilities for goods and services provided to the Group prior to the end of the financial year which are unpaid. The amounts are unsecured, non-interest bearing and are usually paid within 30 days of recognition. Trade and other payables are presented as current liabilities unless payment is not due within 12 months from the reporting date. They are recognised initially at their fair value and subsequently measure at amortised cost using the effective interest method.

**q. Impairment of non-financial assets**

At each reporting date, the Group reviews the carrying values of its tangible and intangible assets to determine whether there is any indication that those assets have been impaired. If such an indication exists, the recoverable amount of the asset, being the higher of the asset's fair value less costs to sell and value in use, is compared to the asset's carrying value. Any excess of the asset's carrying value over its recoverable amount is expensed to the statement of profit or loss and other comprehensive income. Impairment testing is performed annually for intangible assets with indefinite lives. Where it is not possible to estimate the recoverable amount of an individual asset, the Group estimates the recoverable amount of the cash-generating unit to which the asset belongs.

**r. Segment reporting**

An operating segment is a component of the Group that engages in business activities from which it may earn revenues and incurs expenses, including revenues and expenses that relate to transactions with other components of the Group. Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the directors.

**s. Comparative figures**

When required by Accounting Standards, comparative figures have been adjusted to conform to changes in presentation for the current financial period.

## 5. KEY SOURCES OF ESTIMATION UNCERTAINTY AND CRITICAL ACCOUNTING JUDGEMENTS

When preparing the financial statements, management undertakes a number of judgements, estimates and assumptions about recognition and measurement of assets, liabilities, income and expenses. The Directors evaluate estimates and judgments incorporated into the financial report based on historical knowledge and best available current information. Estimates assume a reasonable expectation of future events and are based on current trends and economic data, obtained both externally and within the Group. The actual results may differ from the judgements, estimates and assumptions made by management, and will seldom equal the estimated results. Information about significant judgements, estimates and assumptions that have the most significant effect on recognition and measurement of assets, liabilities, income and expense is provided below.

i. *Share based payments*

The Group measures the cost of equity settled transactions by reference to the fair value of the equity instruments at the date at which they are granted. Fair value is calculated using the Black Scholes valuation model, taking into account the terms and conditions upon which the options were granted. The assumptions used in these valuation models is set out in Note 21.

ii. *Acquisition of PowerLime Inc*

On 27 September 2021 Dominion completed the acquisition of 100% of the issued capital PowerLime Inc (PowerLime). As part consideration the Dominion issued settlement options which were recognised using the Black Scholes valuation model, taking into account the terms and conditions upon which the options were granted. The assumptions used in this valuation model are set out in Note 21.

The directors have determined that at the time of the acquisition, PowerLime lacked the necessary inputs and processes required to generate outputs that have the ability to provide a return on investment to the owner. Consequently, the acquisition of PowerLime did not meet the criteria of a business combination and were outside the scope of AASB3: *Business Combinations*. The acquisition of the shares in PowerLime have been determined by the directors to be assets acquired by an equity-settled share-based payment under AASB 2: *Share Based Payments*. As the fair value of neither the shares in PowerLime nor PowerLime's principal asset being an option to acquire the land on which the Georgia Lime Project is located, could be estimated reliably, the fair value recognised for the acquisition has been measured largely by reference to the fair value of the equity instruments issued by Dominion Minerals Limited as the major part of the consideration provided for the acquisition. Further information regarding the acquisition of PowerLime is provided in Note 29.

iii. *Deferred tax assets*

No members of the Group have generated taxable income in the financial year and as such the Group continues to carry forward tax losses that give rise to deferred tax assets. Given that the Group's projects remain in early exploration stages, it is unlikely that the Group will generate taxable income in the foreseeable future in the absence of asset sales.

Taking account of the above, the deferred tax assets have not been recognised in the financial statements as management does not believe that the members of the Group satisfy the criteria set out in paragraph 35 of AASB 112.

iv. *COVID-19 pandemic*

Judgement has been exercised in considering the impacts that the COVID-19 pandemic has had, or may have, on the Group based on known information. There does not currently appear to be either any significant impact upon the financial statements or any significant uncertainties with respect to events or conditions which may impact the Group unfavourably as at the reporting date as a result of COVID-19.

DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
 FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
 NOTES TO THE FINANCIAL STATEMENTS

6. OTHER INCOME

	2021 \$	2020 \$
ATO cash flow boost	-	21,528
Total other income	-	<b>21,528</b>

7. CLINICAL TRIAL EXPENSES

Over accrual in prior years	-	(191,331)
Total clinical trial expenses	-	<b>(191,331)</b>

*In 2020, accrued expenses relating to the clinical trial had been overestimated in previous years. This resulted in a reversal of the overestimated amount and is presented as a negative expense line item.*

8. EXPENSES

Loss before tax includes the following specific expenses:

Realised gains/(losses) on foreign exchange	(11,835)	(316)
Unrealised gains/(losses) on foreign exchange	(4,275)	(5,732)
Total gain/(loss) on foreign exchange	(16,110)	(6,048)
Depreciation plant and equipment	639	-
Rental expense on operating leases – minimum lease payments	-	2,020

9. CASH AND CASH EQUIVALENTS

Cash at bank	4,887,997	3,178,216
Short term bank deposits - at call	21,556	21,523
	<b>4,909,553</b>	<b>3,199,739</b>

10. TRADE AND OTHER RECEIVABLES - CURRENT

GST/VAT receivable	666	10,488
Other receivables	-	53,308
Less: Provision for doubtful other receivables	-	(51,936)
	<b>666</b>	<b>11,860</b>

During the 2021 financial year, the other receivable outstanding at 31 December 2020 was recovered in full by the Group and related provision for impairment was reversed through the statement of profit and loss.



**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)**  
**FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021**  
**NOTES TO THE FINANCIAL STATEMENTS**

**11. FINANCIAL ASSETS AT VAIR VALUE**

	2021 \$	2020 \$
Option to acquire land	1,256,162	
	<b>1,256,162</b>	<b>-</b>

The Group has entered into an Option Agreement to purchase the property on which the Georgia Lime Project is located. The Option Agreement expires on 22 November 2022. If the Group exercises the option, the Group is required to pay the landholder US\$1,500,000 and the landholder will transfer title to the property and all mineral rights, except oil and gas rights to the Group. Further information regarding the acquisition of PowerLime and the valuation of the option to acquire land is provided in Note 29.

**12. OTHER ASSETS**

**Current**

Prepayments	228,009	45,150
	<b>228,009</b>	<b>45,150</b>

**Non-current**

Prepayments	94,137	-
	<b>94,137</b>	<b>-</b>

**13. INVESTMENTS IN FINANCIAL ASSETS**

Unlisted equity securities at fair value through other comprehensive income	388,547	-
	<b>388,547</b>	<b>-</b>

In December 2021, Dominion invested C\$350,000 to acquire a minority stake in Luna Lithium, a private Canadian company exploring the Pilot Peak lithium brine project in Nevada, USA.

The valuation inputs for the investment are Level 2 inputs being the price at which Luna Lithium raised capital in an arm's length transaction in December 2021.

**14. INTANGIBLE ASSETS**

Computer hardware and software – at cost	24,658	13,152
Less: Accumulated depreciation	(13,791)	(13,152)
	<b>10,867</b>	<b>-</b>

DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
 FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
 NOTES TO THE FINANCIAL STATEMENTS

**15. TRADE AND OTHER PAYABLES - CURRENT**

	2021 \$	2020 \$
Trade payables	137,086	202
Other payables and accruals	27,404	84,267
	<b>164,490</b>	<b>84,469</b>

Trade payables and accruals are unsecured, non-interest bearing and due 30 days from the date of recognition.

**16. INCOME TAX**

**a) The components of income tax expense comprise**

Current tax	-	-
Under/(over) provision in prior years (current tax)	-	-
Total income tax benefit/ (expense)	-	-

**b) The prima facie tax benefit on loss from ordinary activities before income tax is reconciled to the income tax benefit as follows**

Prima facie tax benefit/ (expense) on loss from ordinary activities before income tax at 26% (2020:27.5% )	(277,509)	(77,547)
Tax effect of:		
Tax rates in other jurisdictions	12,280	-
Change in tax rates	1,028,655	-
Non-assessable R&D tax offset	-	183,593
Other	(53,243)	59,953
Transfer to / (utilisation of tax losses available) not brought to account	(710,183)	(165,998)
Total income tax benefit/ (expense)	-	-

**c) R&D Tax Asset**

Opening balance of R&D tax offset concession claimed	-	-
Less: R&D tax offset received	-	(667,611)
R&D tax offset understated in prior years brought to account in current period	-	667,611
Closing balance of R&D tax offset concession claimed	-	-

For personal use only

DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
NOTES TO THE FINANCIAL STATEMENTS

16. INCOME TAX (continued)

	2021 \$	2020 \$
<b>d) Deferred Tax Asset</b>		
Deferred tax assets not brought into account, the benefits of which will only be realised if the conditions for deductibility set out in Note 1(a) occur:		
Temporary differences	44,849	98,092
Tax losses – operating losses	173,374	18,754,919
	218,223	18,853,011

Tax losses do not expire under current tax legislation. The benefit of the tax losses will only be available if the Company, has complied and continues to comply with conditions for deductibility imposed by current tax legislation and there are no adverse changes to such legislation. Following the change in the nature of the Company's activities during the year ended 31 December 2021, the Company has assessed that it will not satisfy the conditions for the carry forward of tax losses amounting to \$18,163,734 incurred prior to the completion of the acquisition of PowerLime, Inc.

17. ISSUED CAPITAL

	2021 Number	2021 \$	2020 Number	2020 \$
<b>Ordinary Shares fully paid</b>	<b>1,042,835,633</b>	<b>84,213,601</b>	<b>1,042,835,633</b>	<b>84,213,601</b>
<i><u>Movements in shares on issue</u></i>				
Balance at beginning of year	1,042,835,633	84,213,601	1,042,835,633	84,213,601
Capital consolidation [10:1]	(938,551,613)	-	-	-
	104,284,020	84,213,601	1,042,835,633	84,213,601
Shares issued in settlement of accrued Director remuneration	2,816,937	112,677	-	-
Share issued on the acquisition of PowerLime Inc	18,750,000	750,000	-	-
Ordinary shares issued capital raise	100,000,000	4,000,000	-	-
Transaction costs	-	(443,411)	-	-
Balance at end of year	<b>225,850,957</b>	<b>88,632,867</b>	<b>1,042,835,633</b>	<b>84,213,601</b>

Ordinary shares entitle the holder to participate in dividends and the proceeds on winding up of the Group in proportion to the number of and amounts paid on the shares held. On a show of hands every holder of ordinary shares present at a meeting in person or by proxy, is entitled to one vote, and upon a poll each share is entitled to one vote.

**18. RESERVES**

	2021	2020
	\$	\$
Option reserve	259,350	126,790
Foreign currency translation reserve	(765)	-
	<b>258,585</b>	<b>126,790</b>

**a) Option Reserve**

The option reserve records the share-based payment expense on valuation options issued by the Group to directors, employees and other parties. Refer Note 21 for information in relation to the valuation of options issued during the financial year.

**Movement**

Balance at beginning of year	126,790	208,181
Option expense	-	1,874
Options issued	200,012	-
Lapsed/expired options	(67,452)	(83,265)
Balance at end of year	<b>259,350</b>	<b>126,790</b>

**b) Foreign Exchange Translation Reserve**

The foreign exchange translation reserve records exchange differences arising on translation of a foreign controlled subsidiary.

**Movement**

Balance at beginning of year	-	-
Movement during the year	(765)	-
Balance at end of year	<b>(765)</b>	-

**19. CAPITAL MANAGEMENT**

Management controls the capital of the Group in order to maintain an appropriate debt to equity ratio and ensure that the Group can fund its operations and continue as a going concern. The Group's debt and capital includes ordinary share capital and financial liabilities, supported by financial assets. There are no externally imposed capital requirements. Management effectively manages the Group's capital by assessing the Group's financial risks and adjusting its capital structure in response to changes in these risks and in the market. These responses include the management of debt levels, distributions to shareholders and share issues. There have been no changes in the strategy adopted by management to control the capital of the Group since the prior year.

## 20. FINANCIAL RISK MANAGEMENT

### Financial Risk Management Policies

The Group's financial instruments consist mainly of deposits with banks in functional and foreign currencies, short-term investments, and accounts receivable and payable.

**Treasury Risk Management:** The Board, at each of its meetings, analyses financial risk exposure and evaluates treasury management strategies in the context of the most recent economic conditions and forecasts. The Board's overall risk management strategy seeks to assist the Group in meeting its financial targets, whilst minimising potential adverse effects on financial performance. Risk management policies are approved and reviewed on a regular basis.

**Financial Risk Exposures and Management:** The main risks the Group is exposed to through its financial instruments are credit risk, interest rate risk, liquidity risk and foreign currency risk.

*Credit risk exposures:* Exposure to credit risk relating to financial assets arises from the potential non-performance by counterparties of contract obligations that could lead to a financial loss to the Group. The credit risk on financial assets of the Group which have been recognised on the statement of financial position is generally the carrying amount, net of any provisions for doubtful debts.

*Interest rate risk exposures:* Exposure to interest rate risk arises on financial assets and financial liabilities recognised at the end of the reporting period whereby a future change in interest rates will affect future cash flows or the fair value of fixed rate financial instruments. The Group is also exposed to earnings volatility on floating rate instruments. At balance date, the Group does not have material exposure to interest rate risk.

*Liquidity risk:* Liquidity risk arises from the possibility that the Group might encounter difficulty in settling its debts or otherwise meeting its obligations related to financial liabilities. The Group manages liquidity risk by monitoring forecast cash flows and ensuring that adequate facilities or financing options are maintained. At balance date, the Group does not have material exposure to liquidity risk.

*Foreign currency risk:* Exposure to foreign currency risk may result in the fair value or future cash flows of a financial instrument fluctuating due to movement in foreign exchange rates of currencies in which the Group holds financial instruments which are other than the functional currency of the Group. The Group manages foreign currency risk by monitoring forecast foreign currency commitments and foreign exchange rates. At balance date, the Group's exposure to foreign currency risk arises from the US\$ denominated net financial assets of PowerLime Inc of A\$66,522 at an exchange rate of 1.3781.

**Net fair value of financial assets and liabilities:** The net fair value of cash and cash equivalents and non-interest bearing monetary financial assets and the financial liabilities of the Group approximates their carrying amounts. The net fair value of other monetary financial assets and financial liabilities is based upon market prices where a market exists or by discounting the expected future cash flows by the current interest rates for assets and liabilities with similar risk profiles.

**Sensitivity analysis:** The Group has performed a sensitivity analysis relating to its exposure to interest rate and foreign currency exchange rate risks, to assess the effect on reported results and equity which could result from a change in these risks. Management have determined that, at 31 December 2021, the effect on profit and equity as a result of changes in foreign currency exchange rates by +100 basis points or -100 basis points would be \$665 (2020: \$2,205). The effect on profit and equity as a result of changes in interest rates by +100 basis points or -100 basis points would be \$49,096 (2020: \$36,496) additional, or less, interest revenue.

## 21. SHARE-BASED PAYMENTS

	2021	2020
	\$	\$
<i>Recognition of share-based payment expense</i>		
Expense arising from equity-settled share-based payment transactions	6,800	1,874

DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
NOTES TO THE FINANCIAL STATEMENTS

21. SHARE-BASED PAYMENTS continued

Summary of options granted and lapsed during the financial year ended 31 December 2021

The following table illustrates the number and weighted average exercise price (WAEP) of, and movements in, share options issued during the year:

	2021 Number	2021 WAEP	2020 Number	2020 WAEP
Outstanding at the beginning of year	5,250,000	\$0.11	8,250,000	\$0.10
Options lapsed during the year (pre capital consolidation)	(3,000,000)	-	(3,000,000)	-
Capital consolidation	(2,025,000)	-	-	-
	225,000	\$1.10	5,250,000	\$0.11
Options issued during the year	16,187,498	\$0.12	-	-
Options lapsed during the year (post capital consolidation)	(100,000)	\$1.10	-	-
<b>Outstanding at the end of the year</b>	<b>16,312,498</b>		<b>5,250,000</b>	<b>\$0.11</b>
Exercisable at the end of the year	16,312,498	\$0.13	5,250,000	\$0.11
Weighted average remaining contractual life		3.40 years		0.89 years

The fair value of options issued by the Group during the year has been determined using the Black Scholes valuation model, considering the terms and conditions upon which the options were granted. The following assumptions were used:

	Options issued to the vendors of Power Lime	Options issued to the management of Power Lime	Options issued as Director remuneration	Options issued to brokers to the capital raising
Grant date	27 Sep 21	27 Sep 21	1 Nov 21	8 Oct 21
Expiry date	26 Sep 25	26 Sep 25	31 Oct 25	7 Oct 24
Exercise price	\$0.12	\$0.12	\$0.12	\$0.12
Expected volatility	79%	79%	79%	79%
Risk free interest rate	0.48%	0.48%	1.18%	0.67%

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
NOTES TO THE FINANCIAL STATEMENTS**

**21. SHARE-BASED PAYMENTS continued**

	<b>Options issued to the vendors of Power Lime</b>	<b>Options issued to the management of Power Lime</b>	<b>Options issued as Director remuneration</b>	<b>Options issued to brokers to the capital raising</b>
Grant date share price	\$0.04	\$0.04	\$0.04	\$0.04
Fair value per option	\$0.0134	\$0.0134	\$0.0136	\$0.01

**22. COMMITMENTS FOR EXPENDITURES**

The Group held no contractual commitments as at 31 December 2021.

**23. CONTINGENT LIABILITIES AND ASSETS**

The directors are not aware of any other contingent assets or any contingent liabilities that are likely to have a material effect on the results of the Group as disclosed in these financial statements other than the following:

- i. The Group has entered into an Option Agreement to purchase the property on which the Georgia Lime Project is located. The Option Agreement expires on 22 November 2022. If the Group exercises the option, the Group is required to pay the landholder US\$1,500,000 and the landholder will transfer title to the property and all mineral rights, except oil and gas rights to the Group. Further information regarding the acquisition of PowerLime and the valuation of the option to acquire land is provided in Note 11 and Note 29.

**24. RELATED PARTY TRANSACTIONS**

Transactions between related parties are on normal commercial terms and conditions no more favourable than those available to other parties unless otherwise stated.

*Key management personnel compensation:* Details of remuneration of the key management personnel are provided in the Remuneration Report in the Directors' Report.

Loans: There were no loans between the Group and any KMP in the year ended 31 December 2021 (2020: \$Nil).

**25. SEGMENT INFORMATION**

Operating segments are identified, and segment information disclosed, on the basis of internal reports that are regularly provided to, or reviewed by, the Group's chief operating decision maker which, for the Group, is the Board of Directors.

The Group is managed primarily on a geographic basis, that is, the location of the respective areas of interest. Operating segments are therefore determined on the same basis.



DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
 FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
 NOTES TO THE FINANCIAL STATEMENTS

25. SEGMENT INFORMATION (continued)

Activity by segment

**Georgia Lime Project**

On 27 September 2021 the Company acquired PowerLime Inc. The principal asset of PowerLime is an Option Agreement to purchase the property in Georgia, USA, on which the Georgia Lime Project is located.

**Corporate**

Expenditure incurred that is not directly allocated to other segments is reported as corporate costs in the internal reports prepared for the chief operating decision maker.

The following tables present revenue and profit information for the Group's operating segments for the year ended 31 December 2021 and 2020, respectively.

a. Segment performance

Year ended 31 December 2021	Georgia Lime Project	Corporate	Total
Total segment revenue	-	5,612	5,612
Total segment expenditure	(256,493)	(816,460)	(1,072,954)
<b>Segment result</b>	<b>(256,493)</b>	<b>(810,849)</b>	<b>(1,067,342)</b>

  

Year ended 31 December 2020	Georgia Lime Project	Corporate	Total
Total segment revenue	-	694,338	694,338
Total segment expenditure	-	(412,347)	(412,347)
<b>Segment result</b>	<b>-</b>	<b>281,991</b>	<b>281,991</b>

b. Segment assets

	United States	Australia	Total
<b>31 December 2021</b>			
Segment assets	1,459,575	5,428,367	6,887,941
<b>31 December 2020</b>			
Segment assets	-	3,256,749	3,256,749

26. CASH FLOW INFORMATION

	2021	2020
	\$	\$
<b>a) Reconciliation of Cash</b>		
Cash at end of the financial year as shown in the statement of cash flows is reconciled to the related items in the statement of financial position as follows:		
Cash and cash equivalents	4,909,553	3,199,739
<b>b) Reconciliation of Cash Flow from Operations with Loss after Income Tax</b>		
Profit (Loss) after income tax expense	(1,067,342)	281,991
Non-cash flows in loss from ordinary activities		
Depreciation	639	-
Unrealised foreign exchange losses	-	5,732
Non-cash employee benefits expense – option-based payments	6,800	1,874
Changes in operating assets and liabilities		
(Increase) / decrease in receivables and prepayments	-	37,736
Increase / (decrease) in payables	13,034	(160,672)
Increase / (decrease) in provisions	-	-
Net cash (outflow) / inflow from operating activities	<b>(979,417)</b>	<b>166,661</b>
<b>c) Non-cash investing and financing activities</b>		
Issue of options as consideration for the acquisition of PowerLime	143,213	-
Issue of options in settlement of capital raising costs	50,000	-

For personal use only

DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
NOTES TO THE FINANCIAL STATEMENTS

27. EARNINGS PER SHARE

	2021	2020
	\$	\$
Profit (Loss) after income tax benefit attributable to the Group	(1,067,342)	281,991
Weighted average number of shares used as the denominator	<b>No.</b>	<b>No.</b>
Weighted average number of ordinary shares outstanding during the year used in calculation of Basic EPS	127,419,842	104,283,563
Weighted average number of options outstanding which are considered potentially dilutive	-	-
Weighted average number of potential ordinary shares outstanding during the year used in calculation of Diluted EPS	<b>127,419,842</b>	<b>104,283,563</b>

Options and other potential equity securities on issue at the end of the period have not been included in the determination of diluted earnings per share as the Group has incurred a loss for the period and they are therefore not dilutive in nature.

	Cents	Cents
Basic earnings per share	(0.84)	0.30
Diluted earnings per share	(0.84)	0.30

28. REMUNERATION OF AUDITORS

Audit services – PKF Brisbane Audit	55,166	40,250
Non-audit services – Investigating Accountant Report for prospectus	25,000	-
	<b>80,166</b>	<b>40,250</b>

29. CONTROLLED ENTITIES

The consolidated financial statements incorporate the assets, liabilities, and results of the following subsidiaries in accordance with the accounting policy described in Note 3(b).

Name of entity	Country of Incorporation	Class of shares	Equity holding (%)	
			2021	2020
PowerLime Inc	United States	Ordinary	100%	-%

On 27 September 2021, the Company acquired all of the issued capital of PowerLime, Inc (PowerLime) from the shareholders of PowerLime.

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
NOTES TO THE FINANCIAL STATEMENTS**

**29. CONTROLLED ENTITIES (continued)**

The consideration paid by Dominion to the vendors for the acquisition comprised:

	<b>A\$</b>
18,750,000 shares to the former shareholders of PowerLime at A\$0.04	750,000
6,249,998 options to the former shareholders of PowerLime with an exercise price of \$0.12 per option expiring on 16 September 2025	83,750
4,437,500 options to the former management team of PowerLime with an exercise price of \$0.12 per option and expiring on 16 September 2025.	59,463
Payment of the second option equal to US\$150,000 which grants PowerLime the right to acquire the real property located in Early County, South Georgia which is prospective for the development of an advanced high calcium limestone project	206,725
Transaction costs representing legal costs incurred in relation to the acquisition of PowerLime	164,613
	<b>1,264,551</b>

At the time of acquisition, the activities of PowerLime were not considered to be a business for the purposes of AASB 3 *Business Combinations* and as such the acquisition is accounted for as an asset acquisition with the cost allocated to individual identifiable assets on the basis of their relative fair value at the date of acquisition as summarised below:

	<b>PowerLime A\$</b>
<b>Net assets at fair value as at 27 September 2021</b>	
Cash and cash equivalents	8,389
<b>Net assets acquired</b>	<b>8,389</b>
Fair value of consideration	1,264,551
<b>Excess of consideration over fair value of net assets acquired adjusted against the option to acquire the land parcel located in Early County, South Georgia</b>	<b>1,256,162</b>

**30. PARENT ENTITY DISCLOSURES**

The individual financial statements for the parent entity show the following aggregations.

	<b>2021</b>	<b>2020</b>
	<b>\$</b>	<b>\$</b>
Results		
(Loss) / profit for the year	(1,068,109)	281,991
Other comprehensive loss	-	-
<b>Total comprehensive (loss) /profit for the year</b>	<b>(1,068,109)</b>	<b>281,991</b>

DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
 FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
 NOTES TO THE FINANCIAL STATEMENTS

**30. PARENT ENTITY DISCLOSURES (continued)**

	2021	2020
	\$	\$
<b>Financial position</b>		
Current assets	5,028,952	3,199,719
Non-current assets	1,722,098	57,010
	<b>6,751,050</b>	<b>3,256,749</b>
Current liabilities	27,599	84,469
Net assets	<b>6,723,451</b>	<b>3,172,280</b>
Contributed equity	88,632,867	84,213,601
Share-based payments reserve	259,351	126,790
Accumulated losses	(82,168,767)	(81,168,111)
	<b>6,723,451</b>	<b>3,172,280</b>

**Guarantee entered into by the parent entity**

The parent entity did not enter into any guarantees in the current or previous financial year, in relation to the debt of its subsidiaries

**Contingent liabilities of the parent entity**

The parent entity did not have any contingent liabilities as at 31 December 2021 and 31 December 2020,

**Contractual commitments for capital expenditure**

The parent entity did not have any contractual commitments for capital expenditure as at 31 December 2021 or 31 December 2020.

**31. EVENTS SUBSEQUENT TO REPORTING DATE**

There have been no subsequent events that required adjustment to or disclosure in the or the Financial Statements of the Group for the year ended 31 December 2021.

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
FOR THE FINANCIAL YEAR ENDED 31 DECEMBER 2021  
DIRECTORS' DECLARATION**

**DIRECTORS' DECLARATION**

In the opinion of the Directors:

- the financial statements and notes of the Group are in accordance with the *Corporations Act 2001*, including:
  - i. giving a true and fair view of the Company's financial position as at 31 December 2021 and of its performance for the financial year ended on that date; and
  - ii. complying with Accounting Standards, the *Corporations Regulations 2001* and other mandatory professional reporting requirements; and
- the financial statements and notes also comply with International Financial Reporting Standards; and
- there are reasonable grounds to believe that the Group will be able to pay its debts as and when they become due and payable.

This declaration has been made after receiving the declarations required to be made to the Directors in accordance with section 295A of the *Corporations Act 2001* and as recommended under ASX Corporate Governance Council's Corporate Governance Principles for the financial year ended 31 December 2021.



**Dr David Brookes**  
**Chairman**

Adelaide, 29 March 2022

## INDEPENDENT AUDITOR'S REPORT

### TO THE MEMBERS OF DOMINION MINERALS LIMITED

#### Report on the Financial Report

##### Opinion

We have audited the accompanying financial report of Dominion Minerals Limited (the company), which comprises the consolidated statement of financial position as at 31 December 2021, the consolidated statement of profit or loss and other comprehensive income, the consolidated statement of changes in equity and the consolidated statement of cash flows for the year then ended, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the company and the consolidated entity comprising the company and the entities it controlled at the year's end or from time to time during the financial year.

In our opinion the financial report of Dominion Minerals Limited is in accordance with the *Corporations Act 2001*, including:

- a) Giving a true and fair view of the consolidated entity's financial position as at 31 December 2021 and of its performance for the year ended on that date; and
- b) Complying with Australian Accounting Standards and the *Corporations Regulations 2001*.

##### Basis for Opinion

We conducted our audit in accordance with Australian Auditing Standards. Our responsibilities under those standards are further described in the Auditor's Responsibilities for the Audit of the Financial Report section of our report.

We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

##### Independence

We are independent of the consolidated entity in accordance with the auditor independence requirements of the *Corporations Act 2001* and the ethical requirements of the Accounting Professional and Ethical Standards Board's APES 110 *Code of Ethics for Professional Accountants (including Independence Standards)* (the Code) that are relevant to our audit of the financial report in Australia. We have also fulfilled our other ethical responsibilities in accordance with the Code.

##### Key Audit Matters

Key audit matters are those matters that, in our professional judgement, were of most significance in our audit of the financial report of the current period. These matters were addressed in the context of our audit of the financial report as a whole, and in forming our opinion thereon, and we do not provide a separate opinion on these matters. For each matter below, our description of how our audit addressed the matter is provided in that context.

PKF Brisbane Audit ABN 33 873 151 348

Level 6, 10 Eagle Street, Brisbane, QLD 4000 | GPO Box 1568, Brisbane, QLD 4001 | T: +61 7 3839 9733

Brisbane | Rockhampton [www.pkf.com.au](http://www.pkf.com.au)

Liability limited by a scheme approved under Professional Standards Legislation.

PKF Brisbane Pty Ltd. is a member firm of the PKF International Limited family of legally independent firms and does not accept any responsibility or liability for the actions or inactions of any individual member or correspondent firm or firms.

For personal use only

## 1. Accounting for acquisition of PowerLime Inc

### Why significant

As described in Note 29, the consolidated entity has accounted for the acquisition of PowerLime Inc as an asset acquisition, rather than a business combination, as the assets did not meet the definition of a business under accounting standards at the date of acquisition.

Accounting for the acquisition is a key audit matter as the acquisition is central to the company's strategy, and it involves management judgement in determining the acquisition accounting treatment, the fair value of net assets acquired and the fair value of the purchase consideration.

### How our audit addressed the key audit matter

Our audit procedures included, but were not limited to the following:

- reviewing the Stock Purchase Agreement and Option Agreement to understand the key terms and conditions;
- obtaining an understanding of the transaction, including confirming the assessment that the transaction constituted an asset acquisition and not a business combination;
- assessing management's determination of the fair value of consideration paid, the allocation of that consideration to individual identifiable assets acquired (including any intangible assets meeting the definition and recognition criteria in AASB 138 Intangible Assets) and liabilities assumed on a relative fair value basis – and agreeing this to supporting documentation; and
- assessing the adequacy of the related disclosures in Notes 11 and 29 to the financial statements

## 2. Share-based payments

### Why significant

During the year, the company issued 18.75m shares and 16.19m options as share-based payments.

The shares were issued to the vendors of PowerLime Inc ("PowerLime").

The options were issued to:

- the vendors of PowerLime;
- the PowerLime management team;
- Directors (as remuneration); and
- Brokers in connection with the capital raising

Share-based payments is a key audit matter due to:

- the significance of share-based payments to the consolidated entity's financial position as at 31 December 2021; and
- the company valuing the options using the Black Scholes model, where inputs such as volatility and risk-free rate require judgement.

### How our audit addressed the key audit matter

Our audit procedures included, but were not limited to:

- evaluating management's assessment of the valuation and recognition of the options and shares.
- obtaining an understanding of the key terms and conditions of the options and shares by inspecting relevant agreements or other documentation;
- evaluating correspondence with an independent expert engaged to review management's calculations and key assumptions;
- recalculating the estimated fair value of the options using the Black Scholes option valuation methodology, including assessing the reasonableness of the key inputs used in the company's valuation model.
- evaluating the allocation of the fair value of share-based payments to assets acquired, capital raising costs, and profit and loss; and



#### Why significant

Refer to Notes 4(h), 5, 17, 18, 21 and 29 to the financial statements for additional information.

#### How our audit addressed the key audit matter

- reviewing the adequacy of the Group's disclosures in respect of the accounting treatment of share-based payments in the financial statements, including the significant judgments involved, and the accounting policy adopted.

### 3. Funding and liquidity

#### Why significant

The accompanying financial report has been prepared on a going concern basis, which assumes that the consolidated entity will

- be able to pay its debts as and when they become due and payable; and
- continue its operations for the foreseeable future.

As disclosed at note 1(b): Going Concern

The ability of the consolidated entity to continue as a going concern is principally dependent upon the consolidated entity managing its cash reserves in order to balance the execution of its exploration and development strategy with maintaining adequate working capital reserves.

#### How our audit addressed the key audit matter

We evaluated the consolidated entity's funding and liquidity position at 31 December 2021 and the ability of the consolidated entity to balance the execution of its exploration and development strategy with maintaining adequate working capital reserves.

Our work included, but was not limited to:

- reviewing the process undertaken to determine the appropriateness of the use of the going concern basis;
- considering expenditure incurred to date with reference to the proposed use of funds as outlined in the company's Replacement Prospectus dated 9 September 2021; and
- evaluating the consolidated entity's funding and liquidity position at 31 December 2021 and the ability of the consolidated entity to repay its debts as and when they fall due for a minimum of 12 months from the date of signing the financial report.

#### Other Information

The Directors are responsible for the other information. The other information comprises the information included in the consolidated entity's Annual Report, but does not include the financial report and our auditor's report thereon.

Our opinion on the financial report does not cover the other information and we do not express any form of assurance conclusion thereon.

In connection with our audit of the financial report, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial report or our knowledge obtained in the audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report in this regard.

#### Directors' Responsibilities for the Financial Report

The Directors of the company are responsible for the preparation of the financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such

For personal use only

internal control as the Directors determine is necessary to enable the preparation of the financial report that gives a true and fair view and is free from material misstatement, whether due to fraud or error.

In preparing the financial report, the Directors are responsible for assessing the consolidated entity's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Directors either intend to liquidate the consolidated entity or to cease operations, or have no realistic alternative but to do so.

### Auditor's Responsibilities for the Audit of the Financial Report

Our objectives are to obtain reasonable assurance about whether the financial report as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with Australian Auditing Standards will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of this financial report.

As part of an audit in accordance with Australian Auditing Standards, we exercise professional judgement and maintain professional scepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the financial report, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the consolidated entity's internal control.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Directors.
- Conclude on the appropriateness of the Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the consolidated entity's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial report or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the consolidated entity to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the financial report, including the disclosures, and whether the financial report represents the underlying transactions and events in a manner that achieves fair presentation.
- Obtain sufficient appropriate audit evidence regarding the financial information of the entities or business activities within the consolidated entity to express an opinion on the group financial report. We are responsible for the direction, supervision and performance of the group audit. We remain solely responsible for our audit opinion.

We communicate with the Directors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

For personal use only

We also provide the Directors with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, actions taken to eliminate threats or safeguards applied.

From the matters communicated with the Directors, we determine those matters that were of most significance in the audit of the financial report of the current period and are therefore the key audit matters. We describe these matters in our auditor's report unless law or regulation precludes public disclosure about the matter or when, in extremely rare circumstances, we determine that a matter should not be communicated in our report because the adverse consequences of doing so would reasonably be expected to outweigh the public interest benefits of such communication.

### Report on the Remuneration Report

We have audited the Remuneration Report included in the directors' report for the year ended 31 December 2021. The Directors of the company are responsible for the preparation and presentation of the Remuneration Report in accordance with section 300A of the *Corporations Act 2001*. Our responsibility is to express an opinion on the Remuneration Report, based on our audit conducted in accordance with Australian Auditing Standards.

### Opinion

In our opinion, the Remuneration Report of Dominion Minerals Limited for the year ended 31 December 2021 complies with section 300A of the *Corporations Act 2001*.



PKF BRISBANE AUDIT



LIAM MURPHY  
PARTNER

BRISBANE  
29 March 2022

For personal use only

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
SHAREHOLDER INFORMATION**

**Registered Office**

c/- Company Matters Pty Ltd

Level 21, 10 Eagle Street

Brisbane, QLD, 4000

P: +61 7 3334 3900

E: investor@dominion-minerals.com

W: www.dominion-minerals.com

**Share Registry**

Shareholder information in relation to shareholding or share transfer can be obtained by contacting the Company's share registry: Link Market Services, Locked Bag A14, Sydney South, NSW, 1235 Tel: 1300 554 474 Email: [registrars@linkmarketservices.com.au](mailto:registrars@linkmarketservices.com.au) [www.linkmarketservices.com.au](http://www.linkmarketservices.com.au)

For all correspondence to the share registry, please provide your Security-holder Reference Number (SRN) or Holder Identification Number (HIN).

**Change of address**

Changes to your address can be updated online at [www.linkmarketservices.com.au](http://www.linkmarketservices.com.au) or by obtaining a Change of Address Form from the Company's share registry. CHESS sponsored investors must change their address details via their broker.

**Corporate Governance Statement**

The Company will publish its Corporate Governance Statement for the year ended 31 December 2022 at the same time that this Annual Report is published. The Corporate Governance Statement will be available on the Company's website at <https://dominion-minerals.com/investors/corporate-governance/>

**Annual General Meeting**

The Annual General Meeting is scheduled to be held in Brisbane during May 2021 at a date to be determined.

**Annual report mailing list**

All shareholders are entitled to receive the Annual Report. In addition, shareholders may nominate not to receive an annual report by advising the share registry in writing, by fax, or by email, quoting their SRN/HIN.

**Securities exchange listing**

Dominion shares are listed on the Australian Securities Exchange and trade under ASX code DLM.

**ASX Shareholder Disclosures**

The following additional information is required by the Australian Securities Exchange in respect of listed public companies. The information is current as at 28 February 2022.

**Total securities on issue**

	<b>Securities (Listed)</b>	<b>Securities (Unlisted)</b>
Fully paid ordinary shares	207,100,957	-
Options to acquire shares	-	5,250,000
<b>Total</b>	<b>207,100,957</b>	<b>5,250,000</b>

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
SHAREHOLDER INFORMATION**

**Distribution of equity securities – ordinary shares**

Range	Securities	%	No. of holders	%
100,001 and Over	178,635,125	86.26	304	13.08
10,001 to 100,000	24,675,266	11.91	635	27.32
5,001 to 10,000	1,998,553	0.97	264	11.36
1,001 to 5,000	1,624,044	0.78	669	28.79
1 to 1,000	167,969	0.08	452	19.45
<b>Total</b>	<b>207,100,957</b>	<b>100.00</b>	<b>2,324</b>	<b>100.00</b>
Unmarketable Parcels	2,296,755	1.11	1,209	52.02

**Voting rights**

Shareholders in Dominion Minerals Limited have a right to attend and vote at General Meetings. At a General Meeting, individual shareholder may vote in person or by proxy. On a show of hands every member present in person or by proxy shall have one vote. Upon a poll each share shall have one vote. All quoted and unquoted share options, and convertible notes, have no voting rights.

**Substantial shareholders**

The Company has no current notice of any shareholder holding greater than 5% of issued securities.

**Share buy-back**

There is no current or planned buy-back of the Company's shares.

**Twenty largest shareholders - ordinary shares (not subject to escrow)**

Rank	Name	28 Feb 2022	%IC
1	CALAMA HOLDINGS PTY LTD	9,156,250	4.42
2	DITM HOLDINGS PTY LTD	6,250,000	3.02
3	PETER CROKE HOLDINGS PTY LTD	4,600,000	2.22
4	CITICORP NOMINEES PTY LIMITED	4,277,386	2.07
5	GP SECURITIES PTY LTD	4,235,799	2.05
6	ARREDO PTY LTD	3,750,000	1.81
7	YELWAC PTY LTD	2,891,495	1.40
8	SYMINGTON PTY LTD	2,888,750	1.39
9	MRS JANICE ANNETTE CAWLEY	2,881,250	1.39
10	HSBC CUSTODY NOMINEES (AUSTRALIA) LIMITED	2,679,464	1.29
11	DR ALOK JHAMB	2,600,000	1.26
12	FREMONT SAGE LLC	2,500,000	1.21
13	MR FRANCIS XAVIER PARNIS & MRS SALLY JANE PARNIS	2,061,710	1.00
14	MRS RACHAEL ANN CROSSLEY	1,970,000	0.95
15	MR MICHAEL ANDREW WHITING & MRS TRACEY ANNE WHITING	1,818,859	0.88
16	NURRAGI INVESTMENTS PTY LTD	1,816,250	0.88
17	DR DAVID LIONEL BROOKES & MRS ELISABETH BROOKES	1,780,000	0.86
18	BNP PARIBAS NOMINEES PTY LTD HUB24 CUSTODIAL SERV LTD	1,775,520	0.86
19	MRS ELISABETH MARY BROOKES	1,750,000	0.84
20	COOL ENTERPRISES PTY LTD	1,500,000	0.72
20	SHADOW MOUNTAIN HOLDINGS PTY LTD	1,500,000	0.72
	<b>Total</b>	<b>64,682,733</b>	<b>31.23</b>
	<b>Balance of register</b>	<b>142,418,224</b>	<b>68.77</b>
	<b>Grand total</b>	<b>207,100,957</b>	<b>100.00</b>

**DOMINION MINERALS LIMITED (FORMERLY FACTOR THERAPEUTICS LIMITED)  
SHAREHOLDER INFORMATION**

**Twenty largest shareholders - quoted share options**

No share options are quoted.

**Holders of greater than 20% unquoted securities**

Taycol Nominees Pty Ltd holds 5,000,000 unlisted share options representing 30.46% of the 16,412,498 unquoted share options are on issue at 28 February 2022.

As at 28 February 2022 there were 16 holders of unlisted options.

**Escrowed securities**

The following securities were subject to escrow conditions as at 28 February 2022:

- 18,750,000 fully paid ordinary shares subject to escrow until 31 October 2023.
- 16,187,498 unlisted options subject to escrow until 31 October 2023.

**Interests in mineral tenements**

As at 31 December 2021, Dominion did not have an ownership interest in any mineral exploration tenements. The Company's 100% owned U.S. subsidiary, PowerLime, Inc has an option to purchase the Georgia Lime Project in south west Georgia, USA.

**Statement in accordance with ASX Listing Rule 4.10.19**

The following table provides a comparison of expenditure incurred in the period from 1 November 2021 (being the date the Company's securities re-commenced trading on the ASX) to 31 December 2021 in relation to the proposed Use of Funds disclosed in the Replacement Prospectus dated 9 September 2021. The Company has used its cash and assets in a form readily convertible into cash that it had at 1 November 2021 in a manner consistent with its business objectives.

Use of Funds	Expenditure incurred since relisting on 1 November 2021 (Note 1) A\$'000	Use of Funds per Prospectus (Note 2) A\$'000	Actual expenditure as a % of proposed Use of Funds %
<b>YEAR 1</b>			
Exploration expenditure	92	2,326	4%
Corporate costs	62	200	31%
Land acquisition costs	408	2,007	20%
Estimated cash expenses of the Offer	562	461	122%
<b>Total – Year 1</b>	<b>1,124</b>	<b>4,994</b>	<b>23%</b>
<b>YEAR 2</b>			
Exploration expenditure	-	1,407	0%
Corporate costs	-	200	0%
<b>Total – Year 2</b>	<b>-</b>	<b>1,657</b>	<b>0%</b>
<b>Total funds allocated</b>	<b>1,124</b>	<b>6,601</b>	<b>17%</b>
Surplus working capital	388	476	82%
<b>Total</b>	<b>1,512</b>	<b>7,077</b>	<b>21%</b>

**Note 1** – Represents expenditure incurred in the period from 1 November 2021 (being the date the Company's listing on the ASX) to 31 December 2021 analysed according to the categories of expenditure set out in the Use of Funds included at Section 4.6 of the Replacement Prospectus dated 9 September 2021.

**Note 2** – Represents the Proposed Use of Funds for the 24-month period following listing as set out in Section 4.6 of the Prospectus dated 9 September 2021.

**FACTOR THERAPEUTICS LIMITED AND CONTROLLED ENTITIES  
CORPORATE DIRECTORY**

**Directors**

Dr David Brookes, Chairman  
Anastasios Arima, Non-Executive Director  
Dominic Allen, Executive Director

**Company Secretary**

Stephen Kelly

**Registered Office**

c/- Company Matters Pty Ltd  
Level 21, 10 Eagle Street  
Brisbane, QLD, 4000  
P: +61 7 3334 3900  
E: investor@factor-therapeutics.com  
W: www.factor-therapeutics.com

**Australian Business Number**

45 101 955 088

**Securities Exchange Listing**

Australian Securities Exchange  
ASX Code: DLM

**Auditors**

PKF Brisbane Audit  
Brisbane  
Australia

**Share Registry**

Link Market Services Limited  
Locked Bag A14  
Sydney South NSW 1235  
Australia  
P: 1300 554 474  
F: (02) 9287 0303  
W: www.linkmarketservices.com.au

For personal use only